

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 2515/0004	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/CA00/00078	International filing date (day/month/year) 28/01/2000	Priority date (day/month/year) 29/01/1999
International Patent Classification (IPC) or national classification and IPC C11B3/00		
Applicant ATLANTIS MARINE INC. et al.		

<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 5 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of sheets.</p>
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> I <input checked="" type="checkbox"/> Basis of the report II <input type="checkbox"/> Priority III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability IV <input type="checkbox"/> Lack of unity of invention V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement VI <input type="checkbox"/> Certain documents cited VII <input checked="" type="checkbox"/> Certain defects in the international application VIII <input checked="" type="checkbox"/> Certain observations on the international application

Date of submission of the demand 23/08/2000	Date of completion of this report 19.04.2001
Name and mailing address of the international preliminary examining authority: European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Boonen, J Telephone No. +49 89 2399 8513



INTERNATIONAL PRELIMINARY
EXAMINATION REPORT

International application No. PCT/CA00/00078

I. Basis of the report

1. With regard to the elements of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, pages:

1-34 as originally filed

Claims, No.:

1-74 as originally filed

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- the language of publication of the international application (under Rule 48.3(b)).
- the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- contained in the international application in written form.
- filed together with the international application in computer readable form.
- furnished subsequently to this Authority in written form.
- furnished subsequently to this Authority in computer readable form.
- The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- the description, pages:
- the claims, Nos.:
- the drawings, sheets:

5. This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):



**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/CA00/00078

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes: Claims
	No: Claims 1-74
Inventive step (IS)	Yes: Claims
	No: Claims 1-74
Industrial applicability (IA)	Yes: Claims 1-74
	No: Claims

2. Citations and explanations
see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/CA00/00078

R It m V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. The present claims 1 to 30 are not novel contrary to the requirements of Article 33(2) PCT.

A process of refining marine oil including contacting the oil with silica under vacuum, bleaching clay and separation of those products is known from document D1 XP-000909116 page 336, top of right column.

The blubber of harp seal was extracted and refined and deodorised under vacuum.

From document D2 US-A-5 855 944 (claims 1 to 29) it is known to treat the marine oil with silica.

The Applicant argued that the claimed process does not involve the addition of alkali.

However, the claim 1 requires that an effective amount of bleaching clay be added.

2. The present claims 31 to 47 are not novel as the refined marine mammal oil is known from document D1.

The mere fact that the marine oil of the application is more pure, can not make it object of patentable matter.

3. The present claims 48 to 60 are not novel as the use of refined mammal marine oil is known from document D3 XP-000908868 (abstract, materials, discussion).

From document D3 it is known that the omega-3 fatty acids have a positive effect to prevent heart disease.

The use of refined marine oil is therefore known as pharmaceutical and as food product for humans from D3.

The higher quality of the oils of the application can not make it patentable.

4. The present claims 61 to 70 are not allowable.

These claims represent a method for treatment of the human and animal body by therapy which can not be patented.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/CA00/00078

5. The present claims 71 to 74 are not novel for the same reasons as given under point 3.

Re Item VII

Certain defects in the international application

1. Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the documents D1 to D3 is not mentioned in the description, nor are these documents identified therein.

Re Item VIII

Certain observations on the international application

1. The following features appear to be essential to the invention:

Deodorisation temperature as given on page 5.

Treating temperature under silica gel as given on page 8.

These features should be included in the present claims 1 and 3 (Article 6 PCT).



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/06, 9/10, 31/00		A3	(11) International Publication Number: WO 99/02133
			(43) International Publication Date: 21 January 1999 (21.01.99)
(21) International Application Number: PCT/EP98/05046		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 8 July 1998 (08.07.98)			
(30) Priority Data: 97202096.0 8 July 1997 (08.07.97) EP			
(71) Applicant (for all designated States except US): GIST-BROCADES B.V. [NL/NL]; Wateringseweg 1, P.O. Box 1, NL-2600 MA Delft (NL).			
(72) Inventors; and		Published	
(75) Inventors/Applicants (for US only): LEFEVRE, Jean-Marie [FR/FR]; 30, rue des Trois Cailloux, F-80000 Amiens (FR). EDENS, Lippo [NL/NL]; Hoflaan 118, NL-3062 JL Rotterdam (NL).		With international search report.	
(74) Agents: SWINKELS, Bart, Willem et al.; Gist-Brocades B.V., Patents and Trademarks Dept., Wateringseweg 1, P.O. Box 1, NL-2600 MA DELFT (NL).		(88) Date of publication of the international search report: 1 April 1999 (01.04.99)	

(54) Title: TOPICAL APPLICATION OF A COMBINATION OF BENZOYL PEROXIDE AND A SECOND ACTIVE INGREDIENT

(57) Abstract

The present invention discloses a multicompartiment dispensing system separately containing a first composition comprising benzoyl peroxide and a second composition comprising a second active ingredient, preferably an antimicrobial agent. Said first and second composition generate a final composition when mixed upon dispensing, said final composition being effective to apply an effective combination of benzoyl peroxide and said second active ingredient.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Topical application of a combination of benzoyl peroxide and a second active ingredient

5

Field of the invention

The present invention relates to the field of topical application of a combination of incompatible active ingredients, one being benzoyl peroxide.

Background of the invention

Acne vulgaris is a skin disorder frequently occurring in young people. It is a disorder of the sebaceous follicles and is associated with the sharp increase in androgen production during adolescence. Hyperproduction of sebum and inflammation caused by proliferation of *Propionibacterium acne* are associated with this skin disorder.

Erythromycin, or a mixture of erythromycin and clindamycin, is commonly used for the treatment of acne. However, propionibacterial resistance to these antibiotics is a growing concern because of its high incidence (Eady et al. (1993), Br. Med. J. 306: 555-556), the resistance to high concentrations of erythromycin and the cross resistance to clindamycin (Eady et al. (1989), Br. J. Dermatol. 121: 51-57). One way to minimize the selective pressure towards resistancies is to combine the antibiotic with benzoyl peroxide.

Benzoyl peroxide is clinically effective because of its bactericidal activity against *Propionibacterium acnes* as well as through its mild keratinolytic effect.

Unfortunately, several factors hamper the development of convenient topical formulations containing both erythromycin as well as benzoylperoxide.

For example, erythromycin can be stably formulated only in high concentrations of suitable solvents such as ethanol (Brisaert et al. (1996), Pharm. World Sci. 18: 182-186), whereas stability in formulations containing high levels of water is unacceptably low. However, topical

- 2 -

application of high concentrations of ethanol is undesirable because of its irritancy to the skin.

In contrast, the stability of benzoyl peroxide in solvents like ethanol is low. Long term stability of benzoyl peroxide can only be guaranteed in compositions providing a low benzoyl peroxide solubility (Chellquist and Gorman (1992), Pharm. Res. 9: 1341-1346). In addition, benzoyl peroxide is extremely reactive, because of instability of the O-O bond. Consequently, benzoyl peroxide can be expected to have a deleterious effect on the chemical stability of other compounds mixed with benzoyl peroxide.

Currently, for topical application of a combination of benzoyl peroxide and erythromycin, a suitable solvent has to be added to both compounds being individually packed as a powder, whereupon the resulting solution in turn has to be mixed into a topical gel. It is highly desirable to avail of a less cumbersome method to apply these compounds.

Description of the invention

20

The present invention provides a convenient solution to the above problems by applying a multicompartiment dispensing system to enable separate containment of individual compositions, i.e. a first composition comprising benzoyl peroxide and a second composition comprising a second active ingredient. According to the invention, said first and second composition generate a final composition when mixed upon delivery, said final composition being effective to apply benzoyl peroxide as well as the second active ingredient in an effective form. The mixing of the individual compositions thereby may occur either *in situ* or in the dispensing system prior to delivery.

The present invention further discloses a method to produce an effective composition comprising benzoyl peroxide and a second active ingredient by *in situ* mixing of two individual compositions, each comprising a predetermined amount of either benzoyl peroxide or a second active ingredient.

- 3 -

The use of a multicompartiment dispensing system according to the invention enables the preparation and use of separate compositions, on the one hand a composition comprising benzoyl peroxide as the active ingredient and on the other hand a composition comprising a second active ingredient. These separate compositions are prepared in such a way that the individual requirements for stable formulation of each active ingredient are fulfilled. In addition, the separate compositions are prepared in such a way that the final composition is effective to deliver the active ingredients present in each individual composition in a form suitable and effective for direct application.

Thus, the nature of the first and second composition are determined by on the one hand the stability requirements of each individual active ingredient and on the other hand the desired properties of the final composition.

The second active ingredient is an ingredient which may act in concert with or even synergistically with benzoyl peroxide. Said second active ingredient for instance may be an antimicrobial agent, preferably an antibacterial or antifungal agent. More preferably, said antimicrobial agent is a macrolide antibiotic, such as erythromycin or natamycin, and/or an aminoglycoside antibiotic, such as clindamycin or lincomycin. Another example of an antimicrobial agent which may be combined with benzoyl peroxide is a sphingoid base, like sphingosine or phytosphingosine (Bibel et, al (1992), J. Invest. Dermatol. 98: 269-273).

Typically, a stable composition may be obtained when an active ingredient is formulated as a suspension formulation, e.g. a composition wherein the vehicle is selected to provide a low solubility of the active ingredient. Sedimentation of a suspended active ingredient in a suspension formulation is prevented by the use of a suitable viscosifying or thickening agent. A stable composition of the active ingredient further may be obtained using a high concentration of a non-aqueous solvent in said composition. Examples of such non-aqueous solvents are ethanol or hydric solvents like polyethylene glycol,

- 4 -

butylene glycol, propylene glycol or glycerol. A stable composition of the active ingredient further may be obtained by dissolving a high concentration of the active ingredient in the solvent of choice.

5 The viscosity of the individual compositions is adjusted to the desired level using a viscosifying or thickening agent. The concentration of the viscosifying agent used mainly is determined by the solvent, the pH, and the weight and size of the particles to be kept in 10 suspension. Conveniently, the concentration of the viscosifying agent may range from 0.1-3%. Desirable viscosities may range from 100 to 30.000 cps (Brookfield, 25 °C - 25 rpm), preferably from 1000 to 10.000 cps. It is preferred that the two individual compositions present in 15 the dispenser according to the invention have a substantially similar viscosity.

Examples of viscosifying agents for gellifying an aqueous suspension composition include Carbomer viscosifiers like Carbopol 940 (B.F. Goodrich) and cellulose derivatives 20 like hydroxypropylmethylcellulose, optionally in combination with colloidal magnesium silicate (Veegum). To stabilize suspensions containing particles and/or containing high concentrations of ethanol or hydric solvents like polyethylene glycol, butylene glycol, propylene glycol or 25 glycerol, viscosifying agents which may be considered include xanthans, Carbomer viscosifiers like Carbopol Ultrez 10 or carrageenans like Satia gum UTC 30 (SBI, Benelux).

The concentration of the active ingredient in the stable composition typically depends on both the desired end 30 concentration of said active ingredient in the final composition as well as on the ratio wherein the first and second composition are mixed to obtain the final composition.

The ratio in which the two individual compositions are 35 delivered by the dispensing system can be adjusted as desired. Typically, said ratio may be adjusted to any value within a range varying from 1:1 to 1:50. Preferably, said ratio may vary from 1:2 to 1:20.

- 5 -

To obtain a dilution of one composition into the other is especially advantageous in the case that one composition contains a solvent in a concentration which is too high for direct topical application.

5 A suitable benzoyl peroxide composition for use in the dispensing system according to the invention is for instance an aqueous suspension formulation comprising benzoyl peroxide in a concentration ranging from 2 to 30 % (w/v).

10 Suitable formulations guaranteeing long term stability of benzoyl peroxide compositions at elevated temperature conditions are given by e.g. Chellquist and Gorman (*supra*) and Bollinger *et al.* (J. Pharm. Sci. 66 (1977): 718-722).

15 Typically, end concentrations of benzoyl peroxide on the skin may range from 2% to 15%.

20 The nature of the composition comprising the second active ingredient will depend on the requirements for stable formulation of the second active ingredient.

25 Stable erythromycin compositions are for instance specified by Vandenbossche *et al.* (Int. J. Pharmaceutics, 67 (1991): 195-199). For long term stability at elevated temperatures erythromycin compositions containing high levels of ethanol are preferable (Brisaert *et al.* (1994), Farmaceutisch Tijdschrift voor België, 1-2, 2-5). The use of pure ethanol as a solvent for erythromycin is also advantageous because erythromycin base can be dissolved in concentrations up to 30%. Alternatively, stable erythromycin compositions are suspension formulations of erythromycin, suspended in for instance propylene glycol, PEG 400, isopropanol, or mixtures thereof.

30 Stable aqueous natamycin compositions are described for instance in European Patent Application EP 678241. The stable natamycin compositions disclosed in EP 678241 are suspensions of natamycin crystals in an aqueous medium, wherein sedimentation of the crystals is prevented by the 35 addition of a suitable viscosifying agent, such as xanthan or carrageenan. Additional suitable viscosifiers include Carbomers or related resins.

Stable aqueous clindamycin compositions are for instance specified by Oesterling (J. Pharm. Sciences (1970)

59: 63-67). Using clindamycin, maximum stability is obtained at a pH value of 3-5.

The nature of the final composition further may determine additional properties of one or both individual 5 composition(s). For instance, the pH of the benzoyl peroxide composition and/or the composition comprising the second active ingredient may be adjusted to the desired pH value of the final composition.

In a preferred embodiment of the invention, a 10 multicompartiment dispenser is provided containing a first composition comprising benzoyl peroxide and a second composition comprising erythromycin. Said first composition comprises 5% (w/v) benzoyl peroxide suspended in an aqueous composition adjusted with sodium hydroxide to a pH of 8 - 15 8.5 and comprising Carbopol 940 as a viscosifying agent to reach a Brookfield viscosity between 500 and 5000 cps. Said second composition comprises 30% (w/v) erythromycin dissolved in 96% ethanol and Carbopol Ultrez 10 as a viscosifier. Preferably, the viscosity of the erythromycin 20 composition is comparable to the viscosity of the benzoyl peroxide gel. Said first and second composition are mixed in a ratio of nine parts first to one part second composition, resulting in a final composition having a concentration of about 5% benzoyl peroxide and 3% erythromycin. In this 25 embodiment, the nature of the erythromycin composition, i.e. dissolved in 96% ethanol, specifically requires a delivery ratio of both compositions which ensures a dilution of said erythromycin composition in the final composition of at least about a factor 10.

30 Since erythromycin is more active at an alkaline pH (Heilman and Herrell (1952), Proc. Staff Meetings Mayo Clinic 27: 285-304), the adjustment of the pH to a value of about 8.5 is desirable for optimal activity. However, this pH value has a deleterious effect on erythromycin stability. 35 The use of a dispenser according to the invention ensures that this pH adjustment occurs only after delivery from the dispenser and mixing on the skin, whereby the final pH is brought about by the benzoyl peroxide composition.

In a further embodiment of the invention, the second composition comprises natamycin as the active ingredient.

The solubility of natamycin, and thus its antifungal effectiveness, is optimal in the higher or lower pH ranges, e.g. around pH 3. Contrary, its stability in these pH ranges is rather low. Therefore, the use of a dispenser according to the invention allows for the combination of a concentrated stable natamycin composition with a stable but acidic benzoyl peroxide composition.

10 The dispensing system used is not critical to the invention. The present invention contemplates any dispensing system which allows for a separate containment as well as a simultaneous dosing (dispensing) of the individual compositions. Examples of suitable dispensing systems are 15 given in WO 97/27841. A preferred multicompartiment dispensing system is a dispenser containing two differently-sized compartments. Such a dispenser enables the dispensing of unequal amounts of two different compositions.

20 Care should be taken to use metal parts which are teflon-coated or nylon-coated (Rilsan process), since benzoyl peroxide is a rather corrosive compound.

The dispensing system according to the invention provides a convenient way to topically deliver a combination of benzoyl peroxide and a second active ingredient.

25

Example 1

Topical application of benzoyl peroxide and erythromycin

Benzamycin® is a pharmaceutical product marketed by 30 Dermik (USA) against serious forms of acne. The product consists of a mixture of 3% erythromycin and 5% benzoyl peroxide. Owing to the chemical incompatibility of erythromycin and benzoyl peroxide, the product comes as two separate jars, one containing erythromycin and one 35 containing a benzoyl peroxide gel. Prior to use, erythromycin and benzoyl peroxide have to be mixed and refrigerated to allow a maximal use period of 3 months by the patient.

- 8 -

A two chamber dispenser was supplied by CosmoCair (Gist-brocades, Delft, the Netherlands). This "Symbio" dispenser combines in one housing a normal and an air-free lotion pump, both activated by the same actuator. Each one of the two pumps is connected to its own individual chamber. The air-free lotion pump is connected with a small cartridge equipped with a plunger in the bottom of the cartridge. The other pump is connected with a diptube and dispenses the formulation from the largest chamber. When the dispenser is assembled, the filled cartridge is (partly) submerged in the formulation contained in the largest chamber. During storage and use, the formulations contained in the cartridge and the largest chamber are kept completely separated.

Upon actuation, the dispenser delivers 0.4 grams of formulation, approx. 0.36 ml from the largest chamber and 0.04 ml from the cartridge. Both product streams are kept completely separated until they are ejected from the orifices of the dispenser.

To mimic Benzamycin® in terms of final concentrations of benzoyl peroxide and erythromycin on the skin, stable formulations of benzoyl peroxide and erythromycin were used to fill the two compartments of the Symbio dispenser.

To prepare a slightly viscous suspension of benzoyl peroxide, 2.0 grams of Carbopol Ultrez 10 (B.F. Goodrich) was carefully added to 450 ml of water. Subsequently 60 grams of aceton were added as well as 43.7 grams of benzoyl peroxide (Genfarma, the Netherlands). Using 8N NaOH, the pH of the solution was raised to pH 8.0 and water was added to obtain a final volume of 600 grams. Finally the suspension was homogenized with an Ultra-turrax. The next morning the suspension was centrifuged for 10 minutes at 5000 rpm in a Sorvall centrifuge to remove any air bubbles, if necessary carefully homogenized again and filled in the largest chamber of the dispenser.

To prepare a 10-times concentrated solution of erythromycin, 20 grams butylene glycol, 1.0 grams Carbopol Ultrez 10 and 49 grams of absolute ethanol were added to a glass beaker. Subsequently 30 grams of erythromycin (Genfarma, the Netherlands) was added and the mixture was

- 9 -

mixed at 40 °C until a clear solution was obtained. Finally this solution was centrifuged to remove any air bubbles and filled into a cartridge. To close the cartridge, the plastic plunger was applied in such a way that no residual air was 5 left between the erythromycin concentrate and the plunger.

After attachment of the filled cartridge to the airfree micropump and assembly of the pumphead with the benzoyl peroxide filled container, the pump was primed to prepare for dispensing of the two formulations on the skin.

10 Manual mixing of the erythromycin concentrate with the co-dispensed benzoyl peroxide on the skin yielded a mixture containing 3% erythromycin and 5% benzoyl peroxide.

- 10 -

Claims

1. A multicompartiment dispensing system separately containing a first composition comprising benzoyl peroxide and a second composition comprising a second active ingredient, said first and second composition generating a final composition when mixed upon dispensing, and said final composition being effective to apply a combination of benzoyl peroxide and said second active ingredient.

10

2. The dispensing system of claim 1, wherein the benzoyl peroxide composition is an aqueous suspension formulation, further comprising a viscosifying agent.

15 3. The dispensing system of claim 1 or 2, wherein the second active ingredient is an antimicrobial agent.

20 4. The dispensing system of claim 3 wherein the antimicrobial agent is a macrolide and/or an aminoglycoside antibiotic.

5. The dispensing system of claim 4, wherein the macrolide antibiotic is erythromycin or natamycin.


25 6. The dispensing system of claim 5, wherein the erythromycin composition is a solution of erythromycin in ethanol, further comprising a suitable viscosifying agent.

30 7. A method to produce an effective composition comprising benzoyl peroxide and a second active ingredient by *in situ* mixing of two individual compositions, each comprising a predetermined amount of either benzoyl peroxide or said second active ingredient.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification ⁷ : C11B 3/00, A23D 9/00, A23L 1/30, A23K 1/16, A61K 31/20, 31/23, A61P 1/00, 3/00, 9/00, 17/00, 25/00, 29/00, 37/00		A1	(11) International Publication Number: WO 00/44862 (43) International Publication Date: 3 August 2000 (03.08.00)
(21) International Application Number: PCT/CA00/00078 (22) International Filing Date: 28 January 2000 (28.01.00)		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(30) Priority Data: 2,260,397 29 January 1999 (29.01.99) CA		(Published) <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant (for all designated States except US): ATLANTIS MARINE INC. [CA/CA]; Scotia Centre, Suite 503, 235 Water Street, St. John's, Newfoundland A1C 1B6 (CA). (72) Inventor; and (75) Inventor/Applicant (for US only): MAG, Ted [CA/CA]; 35 Old Church Road, King City, Ontario L7B 1K4 (CA). (74) Agent: DEETH WILLIAMS WALL; National Bank Building, Suite 400, 150 York Street, Toronto, Ontario M5H 3S5 (CA).			
(54) Title: PROCESS OF CONVERTING RENDERED TRIGLYCERIDE OIL FROM MARINE SOURCES INTO BLAND, STABLE OIL			
(57) Abstract			
<p>Triglyceride oil derived from marine sources, mammalian and fish, is treated with a silica at relatively low temperature under vacuum and is then further treated with a bleaching clay under vacuum and at higher temperature. The silica and the bleaching clay are then separated from the oil. The oil treated by this method is essentially free of proteinaceous materials, phosphatides and mucilage, pro-oxidant metals and very low in colored compounds, and is suitable for deodorizing. The deodorized oil is completely bland, unchanged in the concentration of the long-chain highly unsaturated fatty acids (EPA, DPA and DHA), very low in color, peroxides and secondary oxidation products, free of pesticides and has very good flavor stability. The method avoids the use of any chemicals, such as in the acid and base treatments required in conventional degumming and alkali refining of oils of marine origin. This avoids the formation of artifacts in the oil and trace contamination with chemicals. It also reduces the number of process steps required to produce deodorized food oil from marine sources, which is advantageous in respect to oil quality, process losses and processing costs. The method is especially environmentally advantageous, since it avoids the need for soapstock and waste water processing entirely. Refined oil produced by the method is useful as a nutritional supplement and in methods of therapy or medical treatment.</p>			



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						



INTERNATIONAL SEARCH REPORT

In. .ational application No.
PCT/CA 00/00078

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 61-70 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.



INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 00/00078

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7	C11B3/00	A23D9/00	A23L1/30	A23K1/16	A61K31/20
	A61K31/23	A61P1/00	A61P3/00	A61P9/00	A61P17/00
	A61P25/00	A61P29/00	A61P37/00		

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C11B A23D A61K A23L A23K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>E. VOGNID ET AL.: "Effects of dietary marine oils and olive oil on fatty acid composition, platelet membrane fluidity, platelet responses, and serum lipids in healthy humans"</p> <p>LIPIDS, vol. 33, no. 4, 1998, page 427-436 XP000908868 CHAMPAIGN, IL, US ISSN: 0024-4201 page 427, abstract page 428, column 1, last paragraph</p>	31, 48, 61-67
A		1, 20, 21, 31, 32, 72-74

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

11 May 2000

Date of mailing of the international search report

22.05.2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Dekeirel, M




INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 00/00078

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	U.N. WANASUNDARA ET AL.: "Antioxidant and pro-oxidant activity of green tea extracts in marine oils" FOOD CHEMISTRY., vol. 63, no. 3, 1998, pages 335-342, XP000909116 ELSEVIER SCIENCE PUBLISHERS LTD., GB ISSN: 0308-8146 page 338, column 1; table 1	33-35,71
Y	DE 36 43 848 A (NATEC INST NATURWISS) 1 September 1988 (1988-09-01) page 2, line 46 - line 49 page 3, line 50 - line 61 claims 1,4,5,9	1-3,10, 20-23, 31-35, 43,51, 55,72
Y	US 5 855 944 A (KOSCHINSKI INGO ET AL) 5 January 1999 (1999-01-05) cited in the application column 3, line 35 - line 38 examples 5-8 claims 1,2	1-3,10, 20-23, 31-35, 43,51, 55,72
A	US 5 069 829 A (VAN DALEN JOSEF P ET AL) 3 December 1991 (1991-12-03) cited in the application column 1, line 8 - line 12 claims 1,2,9-11	1-4,6, 31,32
A	WO 96 28150 A (ERIKSEN MARIT) 19 September 1996 (1996-09-19) page 2	31-42,72



PCT

INTERNATIONAL SEARCH REPORT

(PCT Artcl 18 and Rul s 43 and 44)

Applicant's or agent's file reference 2515/0004	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/CA 00/ 00078	International filing date (day/month/year) 28/01/2000	(Earliest) Priority Date (day/month/year) 29/01/1999
Applicant ATLANTIS MARINE INC. et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.

It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing :

contained in the international application in written form.

filed together with the international application in computer readable form.

furnished subsequently to this Authority in written form.

furnished subsequently to this Authority in computer readable form.

the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. Certain claims were found unsearchable (See Box I).

3. Unity of invention is lacking (see Box II).

4. With regard to the title,

the text is approved as submitted by the applicant.

the text has been established by this Authority to read as follows:

5. With regard to the abstract,

the text is approved as submitted by the applicant.

the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is Figure No.

as suggested by the applicant.

because the applicant failed to suggest a figure.

because this figure better characterizes the invention.

 None of the figures.

INTERNATIONAL SEARCH REPORT

Int. Application No

PCT/EP 98/05046

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 A61K9/06 A61K9/10 A61K31/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category ^a	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CA 2 015 111 A (WOO ET AL.) 23 October 1991 see page 6, line 10 - page 7, line 1 see claims 1,4,5,11-13,72-79 ---	1-7
Y	GB 2 088 717 A (RORER INTERNATIONAL) 16 June 1982 see the whole document ---	1-7
Y	WO 93 15726 A (BAROODY ET AL.) 19 August 1993 see page 7, line 9 - page 11, line 16 ---	1-7
Y	US 5 538 732 A (SMITH ET AL.) 23 July 1996 see column 5, line 18 - line 21 see claims 1-29 ---	1-7
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

^a Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

21 December 1998

Date of mailing of the international search report

14/01/1999

Name and mailing address of the ISA
 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
 Fax: (+31-70) 340-3016

Authorized officer

Benz, K

INTERNATIONAL SEARCH REPORT

Int'l Application No.
PCT/EP 98/05046

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97 11680 A (SCHERING AKTIENGESELLSCHAFT) 3 April 1997 see claims 1,6,7,14,15 ---	1-7
P,Y	WO 97 27841 A (GIST-BROCADES B.V.) 7 August 1997 cited in the application see page 9, line 1 - page 10, line 14 -----	1-7

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/05046


Patent document cited in search report	Publication date	Patent family member(s)			Publication date
CA 2015111	A	23-10-1991			NONE
GB 2088717	A	16-06-1982	AR	229405 A	15-08-1983
			AT	381452 B	27-10-1986
			AT	285581 A	15-03-1986
			AU	557147 B	11-12-1986
			AU	7202981 A	17-06-1982
			BE	889327 A	16-10-1981
			CA	1179599 A	18-12-1984
			CH	656307 A	30-06-1986
			CH	647147 A	15-01-1985
			DE	3124698 A	08-07-1982
			DK	273981 A	09-09-1982
			FR	2495471 A	11-06-1982
			GB	2090135 A	07-07-1982
			IE	52227 B	19-08-1987
			JP	57099525 A	21-06-1982
			MX	9203750 A	01-09-1992
			NL	8102997 A	01-07-1982
			SE	8103925 A	09-06-1982
			US	4497794 A	05-02-1985
			US	4692329 A	08-09-1987
			ZA	8104215 A	23-02-1983
WO 9315726	A	19-08-1993	AU	3478893 A	03-09-1993
			BR	9305884 A	19-08-1997
			CA	2130341 A, C	19-08-1993
			CN	1077887 A	03-11-1993
			EP	0626844 A	07-12-1994
			FI	943783 A	17-08-1994
			JP	7504168 T	11-05-1995
			MX	9300848 A	31-08-1994
			NO	943045 A	17-08-1994
			NZ	249021 A	27-08-1996
			PL	171127 B	28-03-1997
			SG	48195 A	17-04-1998
			US	5733886 A	31-03-1998
US 5538732	A	23-07-1996	NONE		
WO 9711680	A	03-04-1997	AU	7282796 A	17-04-1997
			CA	2232621 A	03-04-1997
			EP	0854705 A	29-07-1998
			NO	981412 A	12-05-1998
			PL	325978 A	17-08-1998
WO 9727841	A	07-08-1997	AU	1721697 A	22-08-1997
			BR	9702049 A	13-01-1998
			CA	2216169 A	07-08-1997
			EP	0817613 A	14-01-1998

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l Application No	
PCT/CA 00/00078	

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
DE 3643848	A 01-09-1988	NONE		
US 5855944	A 05-01-1999	AT 123799 T		15-06-1995
		CA 2123595 A,C		27-05-1993
		DE 69202986 D		20-07-1995
		DE 69202986 T		02-11-1995
		DK 612346 T		07-08-1995
		WO 9310207 A		27-05-1993
		EP 0612346 A		31-08-1994
		ES 2073936 T		16-08-1995
		FI 942254 A		13-05-1994
		JP 2956909 B		04-10-1999
		JP 7501355 T		09-02-1995
		NO 941808 A		13-05-1994
US 5069829	A 03-12-1991	AT 97948 T		15-12-1993
		AU 626998 B		13-08-1992
		AU 5148390 A		27-09-1990
		CA 2012544 A		21-09-1990
		CS 9001380 A		13-08-1991
		DD 293130 A		22-08-1991
		DE 69004838 D		13-01-1994
		DE 69004838 T		11-05-1994
		DK 389057 T		28-02-1994
		EP 0389057 A		26-09-1990
		ES 2048408 T		16-03-1994
		HU 55825 A,B		28-06-1991
		JP 2676043 B		12-11-1997
		JP 3203998 A		05-09-1991
		SK 277760 B		07-12-1994
		ZA 9002177 A		27-11-1991
WO 9628150	A 19-09-1996	NONE		





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :		A2	(11) International Publication Number:	WO 99/02133
A61K 9/08, 9/10, 31/00			(43) International Publication Date:	21 January 1999 (21.01.99)

(21) International Application Number:	PCT/EP98/05046			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date:	8 July 1998 (08.07.98)			
(30) Priority Data:	97202096.0	8 July 1997 (08.07.97)	EP	
(71) Applicant (for all designated States except US):	GIST-BROCADES B.V. [NL/NL]; Wateringseweg 1, P.O. Box 1, NL-2600 MA Delft (NL).			
(72) Inventors; and				
(75) Inventors/Applicants (for US only):	LEFEVRE, Jean-Marie [FR/FR]; 30, rue des Trois Cailloux, F-80000 Amiens (FR). EDENS, Lippo [NL/NL]; Hoflaan 118, NL-3062 JL Rotterdam (NL).			
(74) Agents:	SWINKELS, Bart, Willem et al.; Gist-Brocades B.V., Patents and Trademarks Dept., Wateringseweg 1, P.O. Box 1, NL-2600 MA DELFT (NL).			

(54) Title: TOPICAL APPLICATION OF A COMBINATION OF BENZOYL PEROXIDE AND A SECOND ACTIVE INGREDIENT

(57) Abstract

The present invention discloses a multicompartiment dispensing system separately containing a first composition comprising benzoyl peroxide and a second composition comprising a second active ingredient, preferably an antimicrobial agent. Said first and second composition generate a final composition when mixed upon dispensing, said final composition being effective to apply an effective combination of benzoyl peroxide and said second active ingredient.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PROCESS OF CONVERTING RENDERED TRIGLYCERIDE OIL FROM MARINE SOURCES INTO BLAND, STABLE OIL

FIELD OF THE INVENTION

5

The invention relates to a commercial scale method of preparing a bland and flavor stable triglyceride food oil rendered from the tissue fat of fish and marine mammals without the use of refining chemicals such as alkali or acid.

10 BACKGROUND OF THE INVENTION

(i) Omega-3 Essential Fatty Acids

Health experts have concluded that a large percentage of the population have a diet which is deficient in long chain, highly unsaturated essential fatty acids. For example, it is estimated that 80% of all Americans have a deficiency. As many as 60 medical conditions are linked to this deficiency or have been identified as benefiting from Omega-3 supplementation.

The three most important of the long chain fatty acids are eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and docosapentaenoic (DPA). These fatty acids are deemed "essential" because they have a vital role in maintaining the integrity and fluidity of the membrane which surrounds human cells and because they cannot be synthesized by the body. Without a healthy membrane, the ability of cells to hold water, nutrients and electrolytes is impaired. As a consequence, the membrane may no longer protect the cell from damage caused by free radicals which are the products of oxidation within the body. They also lose their receptivity to hormones and their ability to relay chemically encoded instructions for cellular repair.

The search by health conscious consumers for foods containing omega-3 fatty acids can be a frustrating one. Given the trend toward mass production and packaging of meals and meal ingredients, consumers have less knowledge of, or influence over the contents of their food. The move by some manufacturers toward mono or polyunsaturated fats as substitutes for saturated fats is a positive step. Generally however, the polyunsaturates most often selected are those derived from vegetable oils which contain significant amounts of omega 6 but little or no omega-3. While omega 6 and omega-3 fatty acids are both necessary to good health, most health experts agree that, they should be consumed in a balance of 4:1 respectively. Today's

Western diet has created a serious imbalance with current consumption on average of 20 times more omega 6 than omega-3. Concerned consumers have begun to look for health food supplements to restore the equilibrium. Three major sources of omega-3 supplements are flaxseed oil, fish oils, and seal oil.

5 The past decade has seen rapid growth in the production of flaxseed and fish oils. Both types of oil are considered to be good dietary sources of polyunsaturated fats but are less effective than seal oil in supplying omega-3 fatty acids. Flaxseed oil contains no EPA, DHA or DPA but rather contains alpha-linolenic acid - a precursor to EPA. There is evidence however that the rate of metabolic conversion can be slow
10 and unreliable. Some research has shown that supplementation with flaxseed oil may result in higher tissue levels of alpha-linolenic acid without any corresponding increase in EPA.

15 Fish oils vary considerably in the type and level of fatty acid composition depending on the particular species and their diets. For example, fish raised by aquaculture tend to have a lower level of omega-3 fatty acids than those in the wild. Some research has shown that seal oil is more beneficial to those at risk of heart disease and diabetes than is fish oil. The relative absence of DPA in fish oil and the slower rate at which the body assimilates EPA and DHA from fish oils have been cited as factors.

20 The most direct and complete source of omega-3 oils is found in the blubber of certain marine mammals, especially the harp seal. Among its advantages is that the body's absorption of omega-3 from seal blubber is faster and more thorough than is the case with flaxseed and fish oils. This is due, in part, to the molecular configurations of the EPA and DHA in seal oil which varies slightly from that found
25 in fish oils. The essential fatty acids found in seal oil include a high level of DPA (up to ten times that of fish oils). There is growing evidence that DPA is the most important of the essential fatty acids in keeping artery walls soft and plaque free. A further advantage of seal oil is that it is more stable than fish oil and less vulnerable to the natural process of oxidation. However, there are challenges in producing a
30 satisfactory grade seal oil for administration as a dietary supplement to humans. Seal oils, like other health food oils, are susceptible the natural process of oxidation. The primary and secondary products of oxidation may give rise to unacceptable flavours and odours in the oil, impair digestibility of the oil, and produce free radicals which can damage or destroy the body's cells.

The causes of oxidation include exposure to air, heat, light ("harmful light" refers to light in the range of about 4,250 - 5,100 angstrom), oxygen and certain metals such as iron. Oxidation of polyunsaturated oils limit their shelf life. As fish and seal oils become oxidized their taste and odour may become objectionable. For 5 example, one study of encapsulated fish and plant oil samples found that many commercially prepared oils had poor oxidative stability (VKS Shuklia, EG Perkins, "Rancidity in encapsulated health-food oils", Inform, vol. 9, no. 10 (Oct. 1998)). Clearly there is a need for nutritional oils that offer higher levels of oxidative stability.

10 Health Canada recommends that the daily diet contain at least 1.8 grams of omega-3 fatty acids. The U.S. Department of Health and Nutrition Services has also acknowledged that health benefits would accrue to the general population if dietary intakes of omega-3 polyunsaturated fatty acids (PUFA) were increased. At present, the average consumption of omega-3 PUFA in North America and Europe is less than one gram per day. The administration of seal oil as a dietary supplement could fill 15 this gap if a suitable refined oil could be produced.

(ii) Oil Refining

20 In the processing of food oils and fats from animal, vegetable and marine sources, it is important to produce edible oil and fat products that have a bland, neutral taste for several months after processing. To obtain an oil with these characteristics, it is essential to remove compounds that give flavor to the oil as well as compounds that are detrimental to oxidative stability. It is also desirable to significantly reduce, if not eliminate, chemical contaminants such as PCBs and pesticides.

25 The concentrations of objectionable compounds vary in the different oils, depending on the source. Many of the common vegetable oils contain phosphatides, colored compounds and their breakdown products, oxidation products of triglycerides, dissolved and suspended proteinaceous material, free fatty acids, pesticides, pro-oxidant metals and pesticides.

30 Oils derived from marine sources, mammalian and fish, are very low in phosphatides and may be low in colored compounds, but proteinaceous and mucilagenous materials, breakdown products from triglyceride oxidation, and concentrations of calcium and magnesium and pro-oxidant metals are more significant, as well as pesticides. Most importantly, these oils are more sensitive to

oxidative deterioration because of the highly unsaturated fatty acids present. They also contain only insignificant amounts of natural antioxidants, such as the tocopherols that are present in significant amounts in most vegetable oils.

5 The oils of marine origin also have a very intense fishy odor and taste, which originates with protein, mucilage and triglyceride breakdown products. The odor and taste compounds and their precursors must be removed to extremely low levels to make the oil more suitable for food uses and to improve their flavor stability after processing.

10 Experience in processing the oils from the above sources has shown that to achieve sufficiently complete removal of objectionable substances requires several 'refining' steps. These refining steps are described for the various oils in Bailey's Industrial Oil & Fat Products, Fifth Edition, Volume 2. The refining steps comprise the following:

15 Degumming – alkali refining – bleaching – deodorizing.

The degumming process serves to remove phosphatides and other mucilagenous compounds from the oil and is especially important with vegetable oils. Water alone, water and acids such as phosphoric acid, or water and other chemicals 20 are used. Using water alone does not remove phosphatides to the required low concentration.

The alkali refining process serves to remove free fatty acids and phosphatides, especially the non-hydratable phosphatides, mucilagenous and proteinaceous material to very low concentrations. Some of the coloured compounds and the trace metals that 25 occur in oils are also removed. Sodium hydroxide solution is commonly used, sometimes after a pretreatment with an acid such as phosphoric acid. Serious disadvantages of the process are that oil losses tend to be high (because of entrainment of oil in the soap phase), and there is a need to remove fat and chemicals from the water in the process to make it acceptable for discharge. U.S. Patent Nos. 30 5,855,944 (Kochinski, 1999) and 5,264,597 (Van Dalen et al., 1993) are two examples of prior art patents that use alkali refining.

The alkali refined oil is water-washed to remove small amounts of soap and phosphatides. Water washing is sometimes replaced by treating the oil with small amounts of silica gel, which serves to remove residual amounts of phosphatides and

soaps before bleaching. This saves some of the water treatment costs associated with alkali refining.

Bleaching with activated bleaching earth is used to remove colored compounds, especially chlorophylloid and carotenoid material, but also small 5 amounts of phosphatides and soap still left in the oil after alkali refining.

Deodorization primarily removes flavor and odor compounds and small amounts of free fatty acids by distillation. The process is carried out at very low pressures and relatively high temperatures (about 260°C) using steam as a carrier gas to strip the volatile flavor and odor compounds and free fatty acids from the oil. The 10 success of this step depends on the oil having been thoroughly 'refined' in the processing steps outlined above, except for removal of free fatty acids. Because of the relatively high temperatures that must be used in deodorizing, inadequate removal of flavor and color precursors easily lead to new formation of such compounds and hence oils of poor flavor and flavor stability and high color.

15 The above sequence of processing, or 'refining' steps is sometimes modified. For example, degumming and alkali refining can be combined in a single operation followed by bleaching and deodorizing.

Further, alkali refining can be omitted in some cases in favor of degumming alone with chemicals and water. This is then followed by an acid treatment of the oil 20 before adding bleaching clay and bleaching the oil, and then deodorizing. Alternatively, chemically degummed oil may be treated with silica gel to reduce phosphatides still further, as is described, for example in U.S. Patent No. 5,069,829 to Van Dalen et al, and in U.S. Patent No. 4,880,574 to Welsh.

When alkali refining is not used, the deodorizing step is relied upon to remove 25 the free fatty acids from the original, relatively high concentration in the oil to the required low concentration, as mentioned earlier. There are, thus, no fatty acid soaps to be processed and waste water to be treated, as in alkali refining, and the process losses are lower. The deodorizing conditions, however must be somewhat more extreme than are applied with alkali refined oils (temperature, time, steam usage). It is 30 important to note that with vegetable oils and animal fats, which do not contain highly unsaturated fatty acids, the danger of isomerization when somewhat extreme deodorizing temperatures and times are used is not a factor, but with unhydrogenated oils of marine origin this has not been done.

Oils of marine origin are invariably alkali refined and may receive an acid pretreatment before alkali refining to precipitate calcium, magnesium and other trace elements, which are then removed in the alkali refining step. The processing of oils of marine origin is described in *Seal Fishery and Product Development*, F. Shahidi, p.

5 109-111, Science Tech Publishing Company, St. John's NF, 1998. Chang in U.S. Patent No. 4,874,629 and Takao in U.S. Patent No. 4,623,488 refer to this along with bleaching as part of the processing steps required to produce fish oils for food use.

Because of their high unsaturation and ease of oxidation and, hence, their great sensitivity with respect to achieving a bland, flavor stable product for use in edible oil
10 products, it is very important to achieve essentially total removal of the deleterious components in the crude oil. This is required even when these oils are hydrogenated to make them more saturated and stable towards oxidation before use as a food. The danger of inadequate removal, especially of soluble proteinaceous materials and of pro-oxidant metals, primarily iron, and of other deleterious compounds when alkali
15 refining is not applied, is considered too great.

As discussed above, there is now emphasis on using oils of marine origin, unhydrogenated, for their special nutritional qualities due to their content of highly unsaturated, long-chain fatty acids (eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic acid, usually described as EPA, DPA and DHA, or as omega-3 fatty
20 acids) in their triglycerides. Hydrogenation to achieve better stability would destroy the special nutritional qualities of these fatty acids. With the unhydrogenated oils, the thorough removal of oil components deleterious to achieving a bland, flavor-stable oil is then even more important than with other oils.

At the same time, it is also advantageous with these highly sensitive oils to
25 reduce the refining steps and eliminate the use of chemicals as much as possible. This minimizes the chances for exposure to air, and the need for repeated heating of the oils, or for extended periods of time, and the chance for the formation of chemical artifacts with the highly unsaturated fatty acids present. If achieved, it would then be possible to provide an oil for nutraceutical and other food uses that has excellent
30 organoleptic properties without any decrease in the concentration of the nutritionally important EPA, DPA and DHA, and with a minimum of breakdown products, free fatty acids, colored compounds, pro-oxidant metals, pesticide residues and chemical artifacts.

SUMMARY OF THE INVENTION

It was found that oils from marine sources, mammalian and fish, can be 'refined' to achieve essentially complete removal of compounds that are deleterious to oil quality without the use of degumming or alkali refining, or the use of any chemical 5 compounds such as acids or bases.

The process of the invention produces polyunsaturated oils that are rich in the omega-3 fatty acids, particular EPA, DHA &, in the case of seal oil, DPA. The resulting oils have low levels of oxidation and high oxidative stability. The oils have very low levels of lipid peroxides and secondary oxidation products. The process 10 provides a marine mammal (preferably seal) oil, or alternatively a fish oil, with its original omega-3 content unchanged and yet with oxidative characteristics superior to those derived from other methods of preparation. In addition to their oxidative stability, the oils derived from mammalian marine sources offer more efficient assimilation in the body, and include DPA as a high value fatty acid.

15 The refined marine oil (from mammalian or fish sources), has the following properties:

- essentially bland in taste,
- essentially odorless,
- when the oil is deodorized, a free fatty acid content below about 0.25 %, 20 preferably below about 0.10 % and most preferably below about 0.08 % or below about 0.06%; when the oil is not deodorized, the free fatty acid content is below about <2%, preferably below about 1 %, below about 0.5% and most preferably below about 0.2% (these values apply to fish oil or seal oil),
- a peroxide value below about 1.5 me/Kg, preferably about 1.0 me/kg or most 25 preferably at about zero me/kg,
- an anisidine value below about 5 and most preferably below about 2,
- iron below about 0.1 mg/kg and most preferably below the detection limit,
- copper below about 0.05 mg/kg, ,
- phosphorus, below about 0.2 mg/kg,
- 30 • all pesticides considered deleterious in the food chain, below their detection limits as preferably measured chromatographically,

- a content of omega-3 fatty acids that is about unchanged from the crude oil, within analysis error, and a flavor stability by organoleptic testing in which no strong flavor development occurs for two months and preferably three months and most preferably 4 months at ambient temperatures when the oil is protected from harmful light radiation and from air, with or without the addition of antioxidants,
- no production of waste water or soapstock byproduct (i.e. it is an environmentally friendly oil).

Preferred marine sources of crude, rendered oil are, for example, the blubber from various seal species and especially harp seal, which is the most abundant in Canadian waters, and fish preferably with a high ratio of edible tissue to offal, such as salmon, mackerel, tuna, bluefish, sardines, anchovies, halibut, capelin and herring, but not limited to these sources.

The process is preferably used on a commercial scale, that is, it is preferably applied to quantities of oil in excess of 1,000 kg.

The rendered, crude oil is preferably first treated with a silica gel under vacuum at a temperature high enough to reduce the oil's viscosity (preferably at the relatively low temperature of around 75°C) and then with bleaching clay at temperatures which also reduce the oil's viscosity (preferably around 100°C). After contact with these materials, they are separated from the oil by filtration or other means. The adsorbent-free oil is then preferably deodorized.

Further, it was found that such oils can be deodorized in modern, conventional edible oil deodorizing equipment to an odor-and flavorless oil under conditions which avoid isomerization of the very sensitive, long-chain, highly unsaturated fatty acids present. The process still removes pesticides to below detectable levels with low concentrations of free fatty acids and oxidation products. The resulting oils are especially suited for nutraceutical uses and in foods requiring oils of bland taste.

The need for soapstock byproduct and waste water processing was entirely avoided and oil losses in processing were significantly reduced.

The invention relates to a process of refining marine oil including:

- contacting the oil with an effective amount of a silica under a vacuum ;
- contacting the oil with an effective amount of a bleaching clay;

- separating the silica from the oil;
- separating the clay from the oil.

The process is usefully performed without the use of an exogenously added alkali or acid.

5 In another variation, the process of is consisting of (or consisting essentially of):

- contacting the oil with an effective amount of a silica under a vacuum;
- contacting the oil with an effective amount of a bleaching clay;
- separating the silica from the oil;
- separating the clay from the oil.

10

In the process, the oil is contacted with the silica before the oil is contacted with the bleaching clay. In a process, the bleaching clay is under a vacuum.

15 The silica preferably includes a silica gel. The oil can be obtained from the fatty tissue of the marine mammal. The marine mammal may be a seal, for example,

a harp seal, harbour seal, ringed seal, hooded seal and grey seal.

Oil from the fatty tissue of a fish can be used in the processes. The fish may be selected from the group including salmon and mackerel.

20 The silica and clay can be separated from the oil by filtration and/or centrifugation. The effective amount of silica gel is preferably from about 0.01% to 3% by weight of oil. The silica gel preferably includes TriSyl S 627 or a Sorbsil

silica.

25 In the process, the oil is preferably contacted with the silica for about 1 to 60 minutes. The effective amount of bleaching clay is preferably from about 0.1% to 3% by weight of oil. The clay can include Tonsil Supreme 120 FF, a Filtral clay or a Pur-

Flo clay. The oil is preferably heated to about 75°C to 110°C after the oil contacts the bleaching clay. The oil preferably contacts the bleaching clay for about 5 to 30 minutes.

30 The process optionally further includes deodorizing the oil. The process of claim 20, wherein deodorization is carried out in the temperature range of about

150°C to 245°C. Deodorization is preferably carried out at a pressure of about 0.1

mm Hg to 7 mm Hg. The oil is preferably exposed to the temperature and pressure for from about 0.5 minutes to 10 minutes. The oil shrinkage is preferably less than about $1.5\% + 1.5 \times \text{FFA}\%$ in the oil by weight of crude oil. The refined oil is essentially free of proteinaceous material, phosphatidic material and mucilagenous material, trace metals and very low in colour. The refined oil preferably includes a free fatty acid content below 0.25% if the oil is deodorized and a free fatty acid content below 2% if the oil is not deodorized, a peroxide value less than about 1.5 me/kg, an anisidine value below 5 and iron below 0.1 mg/kg and a bland flavor. The refined oil preferably includes copper below about 0.05 mg/kg, phosphorous below about 0.2 mg/kg and is essentially free of pesticides. The omega-3 fatty acid concentration is preferably substantially unchanged from the crude oil. The omega-3 fatty acid concentration is preferably changed by less than 1% absolute from the crude oil. The oil preferably has a flavor stability measured by organoleptic testing in which no strong flavor development occurs for at least about 2 months when the oil is stored at ambient temperatures and substantially protected from harmful light radiation and air.

The invention also includes a refined marine mammal oil or seal oil prepared by a process of the invention. The invention includes a refined oil including a free fatty acid content below about 0.25% after deodorization and a free fatty acid content below 2% if the oil is not deodorized. The invention also includes a refined oil including a peroxide value less than about 1.6 me/kg or a refined oil including an anisidine value below about 5. The refined is preferably a seal oil and includes a free fatty acid content below 0.25% after deodorization and and a free fatty acid content below 2% if the oil is not deodorized, a peroxide value less than about 1.5 me/kg, an anisidine value below 5, iron concentration below 0.1 mg/kg and a bland flavor. The oil preferably includes copper below about 0.05 mg/kg, phosphorous below about 0.2 mg/kg, and pesticides essentially undetectable by chromatography. The refined oil preferably has an omega-3 fatty acid concentration substantially unchanged from the crude oil. The refined oil preferably has a flavor stability measured by organoleptic testing in which no strong flavor development occurs for at least about 2 months when the oil is stored at ambient temperatures and protected from harmful light radiation and air. The oil includes marine mammal oil, for example, seal oil, such as harp seal, harbour seal, hooded seal, grey seal and ringed seal. The refined oil may also include

fish oil. Blends of seal oils or fish oils may also be used. The fish oil can be selected from the group including salmon and mackerel. Shark oils are also useful.

Another aspect of the invention relates to an omega-3 fatty acid concentrate, including omega-3 fatty acids of the refined oil of any of claims 31 to 44, 5 concentrated by up to about 80% or 90%. The invention also includes a process for preparing an omega-3 fatty acid concentrate, comprising concentrating the omega-3 fatty acids of the refined oil of any of claims 31 to 44 by up to about 80% or 90%. The invention includes omega-3 fatty acids isolated from the oil of the invention.

Another aspect of the invention relates to a pharmaceutical composition 10 including the refined oil of the invention and a carrier. The pharmaceutical composition may optionally include and carriers and/or diluents for adapting it for oral, nasal, pulmonary, rectal, ocular, transdermal or parenteral administration. They may be in combination with one or more bioactive compound(s), for example, at least one of coenzyme Q10 and an antioxidant.

15 The invention includes a nutritional supplement including the oil of the invention or omega-3 fatty acids of the invention. A nutritional supplement may also include oil or the omega-3 fatty acids and coenzyme Q10 or an antioxidant.

Another embodiment of the invention is a capsule including the oil or the omega-3 fatty acids. The capsule can include a gelatin capsule. Microcapsules are 20 also useful.

Another aspect of the invention is a food product including the oil of the invention. The food product may include a milk product, a salad dressing or a grain product. The milk product may include skim milk, whole milk, 1% milk, 2% milk, sour cream, coffee cream, whipping cream, powdered milk, yogurt and ice cream. 25 The grain product can include bread or baked food.

The invention also includes an animal, bird or fish feed including the oil or the omega-3 fatty acids of the invention. The invention also includes a food product, including the flesh or egg of an animal, bird or fish wherein the animal is raised by feeding the animal the oil, the omega-3 fatty acids or the feed of the invention.

30 The invention also includes a method of medical treatment, therapy or prophylaxis of a disease, condition, disorder or abnormal physical state including

administering an effective amount of the oil, pharmaceutical composition, nutritional supplement, capsule or food product of the invention to a mammal or animal.

The disease, disorder or abnormal physical state can include one or more characteristics selected from the group consisting of inadequate dietary omega-3 fatty

5 acids, an imbalance of essential fatty acids, a deficiency of one or more essential fatty acids including EPA, DHA, DPA, 18:3 omega-3 fatty acid and 18:4 omega-3 fatty acid. The disease can include heart disease, diabetes, hypertriglyceridemia, hypertension, arthritis, psoriasis, stroke, inflammation, immune system disorders or nervous system disorders. The invention also includes a method of medical treatment
10 or prophylaxis of risk factors for a cardiovascular disease, disorder or abnormal physical state, including administering an effective amount of the oil, pharmaceutical composition, nutritional supplement, capsule or food product of the invention to a mammal. A variation of the invention includes a method for promoting normal brain, immune system and heart development in a patient which comprises administering to
15 a mammal an effective amount of the oil, pharmaceutical composition, nutritional supplement, capsule or food product of the invention to a mammal. The invention also includes a method of prophylaxis of a disease, disorder or abnormal physical state in a fetus, infant or child comprising administering an effective amount of the oil, pharmaceutical composition, nutritional supplement, capsule or food product of
20 any of the invention to a mammalian mother. The administered oil preferably includes omega-3 fatty acids selected from the group consisting of EPA, DHA, DPA, 18:3 omega-3 long chain fatty acids and 18:4 omega-3 long chain fatty acids. The amount of oil administered is preferably adequate to provide about 1.8 to 2.5 g or more of omega-3 essential fatty acids per day (for a human). The amount of harp seal
25 oil preferably contains omega-3 essential fatty acids in the range of about 20% to 24% by weight and the amount of oil administered is preferably up to about 10g/day. The amount of harp seal oil preferably contains omega-3 essential fatty acids in the range of about 20% to 24% by weight and preferably the amount of oil administered is less than or greater than about 10g/day. The includes a refined seal oil having about the
30 properties of the seal oil of the invention in one or more of Table 1-6.

The process preferably uses crude oil or foundation oil. The invention includes the use of the oil or the omega-3 fatty acids of the invention for the preparation of a medicament for the treatment of a disease in a mammal. The

invention also includes an oil or the omega-3 fatty acids of the invention for use as an active pharmaceutical substance.

DETAILED DESCRIPTION OF THE INVENTION

Crude oil refers to oil that has been rendered. Crude oil also includes oil that 5 has been centrifuged, allowed to sit for a period of time or otherwise treated so that undesirable components of the oil (eg. proteinaceous matter) settle out from the oil and can be removed.

The processes of the invention are preferably applied to crude oil but they may also be applied to "foundation oil" which refers to crude oil that has undergone one or 10 more partial refinement processes, for example, degumming, desliming and/or water washing (but not alkali or acid refining). In a variation of the invention, other partial refinement processes to remove undesirable oil components (such as proteinaceous materials, phosphatides, mucilage, pro-oxidant metals or colored compounds) may also be used.

15 The crude oil is preferably obtained from the careful rendering of tissue from marine sources, mammalian and fish. To avoid damage to the highly sensitive EPA, DPA and DHA components (from heat, oxidation and contaminants), the oil is preferably heated to 50°C-85°C, more preferably to 60°C- 80°C and preferably to 75°C in a batch reactor under vacuum to exclude air.

20 The vacuum is then broken and nitrogen is bubbled through the oil and a silica, preferably a silica gel, is added. Silica gels that are available for use with oils are suitable. For example, TriSyl S 627, a silica gel manufactured by W. R Grace of Baltimore, MD, USA is a suitable and preferred material. Silica gels are used in amounts of 0.01 % to 3 %, but more preferably in amounts of 0.1 % to 1 % and most 25 preferably at 0.5 %. Other useful silicas include Sorbsil silicas (Crosfield Company, Joliet, Illinois, USA).

Vacuum is restored and the silica is preferably contacted with the oil for 5 to 60 minutes, and more preferably for 10 to 30 minutes and most preferably for 15 minutes under agitation designed to keep the silica particles in uniform suspension.

30 The vacuum is then again broken and replaced with a nitrogen atmosphere and 0.1 % to 3 %, more preferably 0.5 % to 2.0 % and most preferably 1.0 % of a bleaching clay commonly used for processing of oils is added. Tonsil Supreme 120

FF, which is manufactured by Quimica Sumex S.A. de C.V. of Mexico City, Mexico is a preferred clay, but other clays from the same manufacturer and clays from other manufacturers that are used for the purpose of processing oils may be used. For example, Filtral clays (Engelhard Corp., Beachwood, Ohio, USA) and Pur-Flo clays

5 (Oil-Dri Corporation of America, Chicago, Illinois, USA) are useful.

Vacuum is restored and the oil/silica/bleaching clay mixture is preferably heated to 75°C – 110°C, more preferably to 90°C to 105°C, and most preferably to 100°C, and the oil is maintained in this temperature range for 5 to 30 minutes, and most preferably for 15 minutes under agitation. Agitation keeps the silica and clay

10 particles in uniform suspension.

After this period, the oil may be cooled to a desired temperature and filtered, or the oil may be filtered at the treatment temperature and then cooled to a desired temperature. The filtered oil is kept under vacuum or a nitrogen gas blanket. Other means of separating the silica and clay from the oil may be used.

15 The above procedure can be performed in the continuous mode as well as in the batch mode, as will be apparent to those skilled in the art.

The above treatment may be preceded by a degumming process, with or without chemicals, or an alkali refining process using a suitable base. In chemical pretreatments, the benefit of not using any chemicals in the processing of the oil is no

20 longer present.

The processing is completed by subjecting the filtered oil to deodorization under conditions designed to achieve a bland flavor, free fatty acids below 0.08 %, no detectable pesticide concentrations and no change in the concentration of the long-chain, highly unsaturated fatty acids present. These conditions are preferably as

25 follows:

- A temperature of 150°C to 245°C, and more preferably 200°C to 240°C and most preferably 232°C.
- A pressure of 0.5 to 7 mm Hg absolute, and most preferably 2 to 3 mm Hg absolute.
- A time at the above temperatures and pressures of 0.5 to 10 minutes, and more preferably from 2 to 7 minutes and most preferably 5 minutes.

30 A suitable amount of stripping gas, preferably steam or nitrogen.

Commercial scale equipment is available to achieve these process conditions.

EXAMPLE 1

2,400 kg of rendered harp seal blubber oil were pumped into a jacketed, stainless steel reactor equipped with an agitator, a nitrogen addition port and a 5 vacuum system.

The reactor was sealed and evacuated and the oil was then heated to 75°C under agitation.

Vacuum on the reactor was then broken with nitrogen gas and 0.5 % TriSyl S 627 was added to the oil. The reactor was then sealed again and evacuated.

10 Temperature was maintained for 15 minutes of contact time of the silica/oil mixture. Vacuum was then broken with nitrogen gas, the reactor was opened, and 1 % Tonsil Supreme 120 FF bleaching earth was added to the silica/oil mixture. The reactor was closed again, evacuated and the silica/clay/oil mixture was heated to 100°C and kept at that temperature for 15 minutes contact time.

15 The mixture was then cooled to ambient temperature and filtered through a conventional plate & frame filter. The filtered, cooled oil was collected in a nitrogen gas-blanketed, stainless steel storage tank to await deodorization.

The above procedure was repeated with a further 2,400 kg batch of oil.

No waste water stream was produced in processing the oil for deodorization.

20 The two 2,400 kg batches of oil were then deodorized in a thin-film, continuous deodorizer at 230°C and 2-3 mm Hg absolute pressure for 5 minutes exclusive of heating and cooling time.

25 The analytical data of the two combined, approximately 2,400 kg batches of crude, rendered oil, of the silica/clay treated oil and the analytical and organoleptic data of the deodorized oil are given in Table 1.

Table 1.

	<u>Crude</u>	<u>Silica/Clav Treat.</u>	<u>Deodorized.</u>	
5	*FFA, % *PV, me/kg *AV Color, R/Y Flavor./Odour	0.48 4.1 7.9 4.5/30 strongly fishy	0.5 0 6.4 0.2/8.5 fishy	0.06 0 3.8 0.3/5.7 bland/no odor
10	EPA+DPA+DHA, % EPA, % DPA, % DHA, %	20.3 7.6 4.1 8.7	20.4 7.6 4.1 8.7	20.1 7.5 4.0 8.6
15	Phosph., P, mg/kg Copper, Cu, mg/kg Iron, Fe, mg/kg	- - -	- - -	- - -
20	Pesticides, mg/kg	-	-	< detection limit

25 *FFA = free fatty acids; PV = peroxide value; AV = anisidine value (no units). A bland flavour or taste means that the oil does not have a fishy flavor (also referred to as a "strong flavour" in this application). A strong fishy flavor is unpleasant to most persons.

30 Note: All analyses were performed using the relevant Official Methods and Recommended Practices of the American Oil Chemists' Society, Champaign, IL, USA. For pesticides, AOAC Method 970-52-S of the Association of Official Analytical Chemists was used.

Comments on crude and processed oil quality data, Table 1.

35 Crude oil was of relatively good quality. FFA, PV, color, were all acceptably low for oil rendered from edible seal blubber tissue. The AV at 7.9 was relatively high indicating some deterioration of the oil during the rendering process or crude oil storage.

40 Silica/clav treated oil was of excellent quality in respect to color and PV and AV. These data indicate that the oil pretreatment with the types and amounts of adsorbents chosen was removing the oil impurities of concern very thoroughly.

Deodorized oil was of excellent quality in all respects. Most striking was the completely bland taste of the freshly deodorized oil, which is a prerequisite for

maintaining a relatively low taste level, if not a totally bland taste of the oil packaged in capsules, bottles or incorporated into food recipes. Color, FFA, PV and AV were all at levels expected of the best edible vegetable oil or animal fat qualities on the market. Pesticide concentrations were below detection limits for present analytical 5 chemistry methods. The concentration of the long-chain, highly unsaturated fatty acid components of the oil (EPA/DPA/DHA) remained unchanged in the silica/clay as well as in the deodorization treatment.

The above data show that degumming or alkali refining steps in processing of the seal blubber oil were not required to obtain a deodorized oil of excellent quality. It 10 also shows that no chemicals such as acids or bases were required to achieve these results and that deodorization conditions chosen did not have any negative effects on oil quality.

EXAMPLE 2

15 The above described procedure was repeated with a slightly different lot of rendered, crude seal blubber oil. A total of about 15,000 kg of oil were silica/clay treated in seven approximately 2,200 kg batches. The analytical data of the seven combined batches of crude, rendered oil, of the combined silica/clay treated oil and the analytical and organoleptic data of the deodorized oil are given in Table 2.

20

Table 2.

	<u>Crude</u>	<u>Silica/Clay Treat.</u>	<u>Deodorized</u>
25	*FFA, %	0.49	0.07
	*PV, me/kg	4.1	0
	*AV	9.1	3.8
	Color, R/Y	4.9/32	0.3/8.0
	Flavor./Odour	strongly fishy	bland/no odor
30	EPA+DPA+DHA, %	20.4	20.3
	EPA, %	7.6	7.5
	DPA, %	4.1	4.1
	DHA, %	8.7	8.7
35	Phosph., P, mg/kg	0.8	< 0.2
	Copper, Cu, mg/kg	< 0.05	< 0.02
	Iron, Fe, mg/kg	4.3	< 0.05
40	Pesticides, mg/kg	-	< detection limit

*FFA = free fatty acids; PV = peroxide value; AV = anisidine value (no units).

Note: All analyses were carried out using the Official Methods and Recommended

5 Practices of the American Oil Chemists' Society, Champaign, IL, USA.

For pesticides, AOAC Method 970-52-S of the Association of Official Analytical Chemists was used.

Comments on crude and processed oil quality data, Table 2.

10 Crude oil was of relatively good quality. FFA and PV were acceptably low. The AV at 9.1 and the color at 4.9R/32Y were higher than in Example 1 indicating somewhat poorer crude oil quality than that used in Example 1. Iron concentration was 4.3 mg/kg, which is relatively high for satisfactory removal in refining procedures.

15 The silica/clay treated oil was of excellent quality in respect to color and PV and also in respect to AV (see deodorized oil data). The oil had low colour ("low colour" refers to below about 1 Lovibond red on a Lovibond colour comparator). Further, trace metals and phosphorus were essentially completely removed. These data indicate that the oil pretreatment with the types and amounts of adsorbents

20 chosen was removing the oil impurities of concern very thoroughly. This is, of course, a prerequisite for producing a completely bland, odorless oil in deodorizing, as pointed out earlier. No byproducts requiring waste water treatment were produced.

25 Deodorized oil was of excellent quality in all respects. The oil was odorless and completely bland in taste. Color, FFA, and PV and AV, were all at levels expected of the best edible vegetable oil or animal fat qualities on the market. Iron, copper and pesticide concentrations were all below detection limits for present analytical chemistry methods.

30 There was no change in the concentration of the long-chain, highly unsaturated fatty acid components of the oil (EPA/DPA/DHA) as a result of deodorization under the conditions used.

During this relatively long production run, processing losses were determined to be about 2 %. If alkali refining was used, a processing loss of 3.5 % would be expected.

The above data confirm that degumming and alkali refining steps in processing of the seal oil were not required to obtain a deodorized oil of excellent quality by all criteria and that no chemicals were required to achieve this result.

We refine the procedure, for example, to increase silica gel quantity or to use a 5 superior silica gel, and to use high quality seal oil (lower crude oil FFA, peroxide value, anisidine iron as well as other good quality indications) to obtain higher quality refined oil (peroxide value of zero, anisidine value below 2, and preferably below 1, iron below the detection limit, copper below the detection limit, phosphorous below 0.2 mg/kg, pesticides below their detection limits. We also use nitrogen stripping gas 10 to get lower FFA.

We use the procedures described above, with necessary variations, to refine other crude marine oils (preferably seal and fish), including harbour seal, hooded seal, grey seal and ringed seal oils and salmon and mackerel oils (and other fish or seal oils). We measure the FFA, PV, AV, Color, R/Y, Flavour/Odour, EPA+DPA+DH 15 (and individual percentages of these), phosphorous, copper and pesticides and determine that the refined oils have FFA < about 0.25% (when deodorized) and preferably <0.08, PV < about 1.5 and preferably about zero, AV < about 5 and preferably about 2, no flavour or odor (i.e. no fishy taste or odour-a bland oil), low colour, iron below about 0.1 mg/kg, copper below about 0.05mg/kg, phosphorous 20 below about 0.2mg/kg, pesticides below their detection limits and a content of omega-3 fatty acids that is unchanged from the crude oil, within analysis error, and a flavor stability by organoleptic testing in which no strong flavor development occurs for at least 6 weeks at ambient temperatures when the sample is protected from harmful light radiation and from air, with or without the addition of antioxidants. We measure 25 the stability of the oils after storage (preferably in capsules or brown glass bottles) at ambient temperatures (with or without tocopherols such as mixed tocopherols). The oils remain bland with no odour for at least 6 weeks.

Flavor stability evaluation of the deodorized oils

30 Samples of deodorized oil from the above examples were kept in brown glass bottles, nitrogen protected, and with and without 4,000 mg/kg of mixed, soybean oil-derived tocopherols added, at ambient temperature for up to 9 weeks. The samples were flavored by an expert in edible oil flavor evaluation. One sample was kept at 4.5 C without nitrogen protection.

Oil in capsules at ambient temperature was also evaluated. The results were as follows (tocoph. refers to tocopherol).

Table 3.

5		Oil from Example 1 <u>with tocoph.</u> <u>without tocoph.</u>	Oil from Example 2 <u>with tocoph.</u> <u>without</u>
10	Freshly deodorized	bland/no odor	bland/no odor
	After 4 weeks odor	bland/no odor bland/no odor	bland/no odor bland/no
15	After 6 weeks odor	bland/no odor bland/no odor	bland/no odor bland/no
	After 9 weeks odor	bland/no odor bland/no odor	bland/no odor bland/no
20	After 9 weeks, no nitrogen protect. at 4.5 C	bland/no odor	-
	Oil in gelcapsules for 8 weeks	very slight fishy taste	-

Comments on flavor stability data, Table 3.

The above data show that the deodorized oil had excellent flavor stability in spite of its highly unsaturated components. The flavor data prove that the oil was 30 essentially free of proteinaceous, mucilagenous and colored components, which might have led to flavor deterioration due to their breakdown over time and, which could occur independent of oxidation of the highly unsaturated components. The encapsulated oil is far superior in flavor to any capsule oil of marine origin presently available. Laboratory analysis was performed to compare the omega-3 seal oil 35 capsules of the invention to commercially available seal oil capsules.

Table 4

QUALITY COMPARISON - LABORATORY ANALYSIS
OMEGA 3 SEAL OIL CAPSULES

QUALITY INDICATORS	BRAND A	BRAND B	BRAND C	CAPSULES OF THE INVENTION
ESSENTIAL FATTY ACID PROFILE				
EPA mg	27.93	32.75	32.43	39.05
DPA mg	15.19	18.40	18.88	21.01
DHA mg	35.28	37.31	37.27	43.52
18:3 OMEGA 3 mg	2.45	2.35	2.42	2.91
18:4 OMEGA 3 mg	6.37	5.57	6.29	6.81
TOTAL OMEGA 3 mg/capsule	87.22	96.38	97.29	113.30
TOCOPHEROLS µg/capsule	2205 alpha only	390	N/A	2148 alpha, beta, gamma, delta
FREE FATTY ACIDS	0.85%	1.61%	1.52%	0.06%
PEROXIDE VALUE meq/kg	11.7	4.85	1.57	0.40
TBARS VALUE	4.50	4.20	2.56	1.90
TRACE Fe	TBD	TBD	TBD	NIL
METALS Cu	TBD	TBD	TBD	NIL
TOTAL PCB's/POLLUTANTS	1.3	1.4	0.62	NIL
COLOUR	YELLOW	YELLOW	YELLOW	LIGHT/CLEAR
ODOUR	MILD FISHY	FISHY	FISHY	NO ODOUR
FLAVOUR	MILD FISHY WITH SLIGHT AFTER TASTE	FISHY WITH AFTER TASTE	MILD FISHY WITH AFTER TASTE	BLAND WITH NO AFTER TASTE

5

* TBD=To be determined

Explanatory Notes on Table 4

1. All values are based on laboratory analysis of soft-gel, size 10 oval, nominal half-gram capsules sold commercially under the respective brand names.
2. Total omega-3 is a measure of the actual omega-3 content of oil as extracted from capsule samples and weighed. The omegas include EPA (eicosapentaenoic acid), DPA (docosapentaenoic acid), and DHA (docosahexaenoic acid) as well as the 18:3 omega3 and 18:4 omega3 fatty acids. The higher the omega3 content, the more valuable the oil. Note: Fish oils contain little or no DPA with mammalian oil constituting one of the few natural sources of this essential fatty acid.
3. The addition of mixed tocopherols serves as an antioxidant and helps preserve oil quality by absorbing the products of oxidation within the encapsulated oil. This also serves to extend the shelf life of the oil. Tocopherol levels for each brand are reported on the basis of the weight in micrograms per capsule. The capsules of the invention preferably utilize mixed tocopherols from natural sources.
4. Free fatty acids are produced during rendering of the oil and, if not removed during the refining process, can adversely affect colour, foam and cloudiness of the finished product.
5. The peroxide value is the measure of the primary products of natural oxidation in the oil. Reduction of the peroxides during refining to levels at or near zero is highly desirable in order to achieve an oil which is low in oxidation, high in oxidative stability and having maximum shelf life. Oil having peroxide values in excess of 3.0 meq/kg may be considered unacceptable in quality. Failure to reduce peroxides to sufficiently low levels may challenge the antioxidant defence mechanisms of the body and result in the creation of secondary products of oxidation.
6. The TBARS value is a measure of the secondary products of oxidation within the oil. It measures volatile compounds including anisidines which result from the breakdown of peroxides in the oil. The lower the TBARS value, the higher the quality of the oil. An oil having a high TBARS value may challenge the antioxidant defence mechanisms of the body and may exhibit a more pronounced fishy odour and taste, which even in encapsulated form may impair digestibility.

7. The level of trace metals in oil extracted from capsules of the invention is below detection limits. The presence of iron, in particular, is deemed undesirable as it presents a source of ongoing oxidation of the oil.

5 Confirmation of the level of trace metals in other products is expected to be above detection limits.

8. The levels of pesticides, PCBs and other toxic materials in harp seal population in the North Atlantic is among the lowest among any marine mammals in the world and is well below all established international limits of toxicity. Nevertheless, the unique refining process of the invention has

10 ensured the elimination of these background toxicants or their reduction below their respective detection limits.

Example 3

15 The procedure described in Example 1 was repeated with another lot of rendered, crude seal blubber oil which had somewhat different crude oil quality parameters from those given in Examples 1 and 2. A total of about 20,000 kg of oil were silica/clay treated in nine approximately 2,200 kg batches. The analytical data of the nine combined batches of crude rendered oil, of the combined nine batches of silica/clay treated oil and the analytical and organoleptic data of the deodorized oil are given in Table 4.

20

Table 4.

<u>Analyses</u>	<u>Crude</u>	<u>Pretreated</u>	<u>Deodorized</u>
*FFA, %	0.53	0.54	0.03
*PV, me/kg	1.83	0	0
*AV	5.03	3.78	2.33
Totox (2xPV + AV)	8.7	3.6	2.3
Color, R/Y	5/26	0.5/11	0.3/9.9
Flavor/Odor	strongly fishy	fishy	bland/no odor
EPA/DPA/DHA, %	19.6	-	19.4
EPA, %	7.3	-	7.3
DPA, %	4.0	-	3.9
DHA, %	8.3	-	8.2
Phosph., P, mg/kg	0.8	< 0.2	< 0.2
Copper, Cu, mg/kg	< 0.05	< 0.05	< 0.05
Iron, Fe, mg/kg	0.53	< 0.02	< 0.02

Pesticides, mg/kg	< det. limit
*FFA = free fatty acids. PV = peroxide value, AV = anisidine value (no units).	

Note: All analyses were carried out using the Official Methods and Recommended

5 Practices of the American Oil Chemists' Society, Champaign, IL, USA, except the determination of pesticides which used Method 970-52-S of the Association of Official Analytical Chemists of the USA.

Comments on crude and processed oil data, Table 4.

10 Crude oil PV, AV and iron (Fe) content was lower than with the oil used in Examples 1 and 2 and FFA was about the same. The long-chain omega-3 fatty acids at 19.6 % were lower than in the crude oil of Examples 1 and 2 at 20.4 %. There was about 1.0 % moisture in the crude oil (not listed in the table), which affected process losses.

15 The silica/clay treated oil was of excellent quality in respect to color, PV and AV.

Also, phosphorus, iron and copper were very low with iron and copper below the detection limits of accepted analysis methods. These results demonstrated again that alkali refining of the oil is not a prerequisite for preparing the oil for deodorization.

20 Deodorized oil was of excellent quality in all respects. The oil was odourless and essentially bland in taste. Colour, FFA, PV and AV were all at levels expected of the best edible oils of vegetable or animal origin on the market. Iron, copper and pesticides were below the detection limit. There was no significant change in the concentration of the long-chain omega-3 fatty acids EPA, DPA and DHA (19.4 % vs. 19.6 %) as a result of the deodorizing conditions used.

25 The processing losses in this run were determined to be about 3.7 % of which about 2.6 % were due to the silica/clay treatment and deodorization, and about 1.1 % were due to moisture in the crude oil. If alkali refining had been used the losses would have been expected to about 1.5 %, absolute, higher.

Example 4.

The procedure described in Example 1 was repeated with a fourth lot of rendered, crude seal blubber oil which had crude oil quality parameters similar to the oil used in Example 1, especially in respect to the peroxide value and the anisidine value of the oil. A total of about 20,000 kg of oil were silica/clay treated in nine approximately 2,200 kg batches, but only about 11,000 kg were deodorized because of deodorizer equipment problems. The analytical data of the nine combined batches of crude rendered oil, of the nine combined batches of silica/clay treated oil and the analytical and organoleptic data of the deodorized oil are given in Table 5.

10 The silica/clay treatment was chosen to be the same, initially, as used in the other examples, but this was changed after the first 2,200 kg batch from 0.5 % TriSyl 627 to 0.75 %, and from 1 % Tonsil Supreme 124 FF to 1.5 % to try to improve pretreated oil colour, which was judged to be darker than desirable with the first batch processed.

15 **Table 5.**

	<u>Analyses</u>	<u>Crude</u> (pre-ship)	<u>Pretreated</u> (batch spls)	<u>Deodorized</u> (spot samples)
		sample)	averaged)	averaged)
20	FFA, %	0.70	0.71	0.04
	PV, me/kg	5.3	0.06-0.12	0-0.12
	AV	6.5	4.5-5.4	2.1-3.0
	Totox (2xPV + AV)	21.5	4.6-5.6	2.3-3.2
	Color, R/Y	5.7/38	0.5/11	0.5/8
25	Flav/Odor	strongly fishy	fishy	bland/no odor
	*EPA/DPA/DHA, %	19.7	-	19.5
	EPA, %	7.2	-	7.1
	DPA, %	4.0	-	4.0
30	DHA, %	8.5	-	8.4
	Phosph., P, mg/kg	< 0.2	-	< 0.2
	Copper, Cu, mg/kg	< 0.05	-	< 0.05
	Iron, Fe, mg/kg	0.49	-	< 0.02
35	Pesticides, mg/kg	-	-	< det. limit

*FFA = free fatty acids, PV = peroxide value, AV = anisidine value (no units).

Note: All analyses were carried out using the Official Methods and Recommended Practices of the American Oil Chemists' Society, Champaign, IL, USA, except the

5 determination of pesticides which used Method 970-52-S of the Association of Official Analytical Chemists of the USA.

Comments on crude and processed oil data, Table 5.

Crude oil quality was very similar to that of Examples 1 and 2 in respect to 10 PV, AV and iron (Fe) content (Example 2, only). The FFA content was higher at 0.70 % than in any of the previous examples, which had concentrations of about 0.50 %. The long-chain omega-3 fatty acids at 19.7 % were the same as in Example 3 (19.6 %), but lower than in Examples 1 and 2 at 20.4 %.

The silica/clay treated oil was of good quality, except that the colour of the 15 first batch was 0.7 R, which was higher than experienced in the previous examples. With all subsequent pretreatment batches (8 out of a total of 9) Trisyl was increased from 0.5 % to 0.75 % and Tonsil bleaching clay from 1 % to 1.5 %. This reduced colour by 0.2 R/5 Y to 0.5 R/8 Y similar to previous results. PV's and AV's were satisfactory.

20 Deodorized oil was of very good quality in all respects, even though the PV measurements showed values in the range of 0.06-0.12 me/kg. The AV was very low, similar to the oil in Example 3. Phosphorus was at the desired low level and copper and iron were below their respective detection limits. Pesticides could not be detected in the oil. The long-chain omega-3 fatty acids remained essentially unchanged during 25 deodorization (19.5 % compared to 19.7 % in the crude oil).

The processing losses in this run were determined to be about 4.5 %. This was as expected from the higher FFA content and the higher usage of silica and clay.

Flavour stability evaluation of the deodorized oil described in Table 5.

30 Samples of the deodorized oil from Example 4 containing 3,360 me/kg of mixed tocopherols derived from soybean oil were evaluated for flavour stability at 4-5

C (refrigerator temperature) in 150 ml food-approved, opaque plastic bottles. The bottles were nitrogen capped and wrapped in foil to ensure protection of the oil from light. One bottle/month, starting two days after the oil was deodorized, was flavour tested on every second or third day throughout the month by an expert taster by 5 pouring a few ml of oil into a teaspoon and tasting it. After the tasting, the bottle was re-closed, without nitrogen cap, and returned to the refrigerator. After each month another bottle, which had been stored as above, was opened and tested as described above

10 The results were noted by describing the flavour in terms commonly used in the edible oil industry from completely bland (and rarely achieved even with freshly deodorized animal fats or vegetable oils) to denoting a strongly fishy or painty taste and definitely no longer acceptable for consumption.

The results are summarized below in Table 6.

15 **Table 6.**

	<u>Month</u>	<u>Taste</u>	
		<u>At start of month</u>	<u>At end of month</u>
20	Month 1	very slightly buttery, no fish note, nearly bland	slight fish taste, still quite acceptable
25	Month 2	nearly bland, possibly a hint of fish	slight fish taste, slight oxidized note, still quite acceptable
30	Month 3	nearly bland, very slight fish note,	slight fish and oxidized taste, still quite acceptable
35	Month 4	nearly bland, very slight fish note	slight fish and oxidized taste, still quite acceptable
40	Month 5	slight fish note, slightly bitter,	slight fishy/painty/oxidized taste still acceptable
	Month 6	nearly bland slight hint of fish	slight fish and slight bitter taste, still quite acceptable.

Comments on flavour stability.

The above experience shows:

i) Oil in unopened bottles

The deodorized oil in bottles at 4-5 C under nitrogen gas and protected from light retained a nearly bland flavour for at least 6 months and very probably can be stored under these conditions much longer. There were some bottle-to-bottle

5 differences due to handling of the samples and the sensitivity of omega-3 fatty acid oil to oxidation.

i) Oil in frequently opened bottles after 1 month

The deodorized oil after opening (and no longer under a nitrogen gas cap)

10 deteriorates slowly over one month at 4-5 C. This deterioration still leaves the oil with an acceptable taste for use as a food after one month.

The flavour stability tests show that the oil was well refined, that is, it was essentially free of proteinaceous, mucilagenous and coloured components, which might have led to flavour deterioration due to the breakdown of these compounds 15 over time and which would occur independently of oxidation of the highly unsaturated fatty acid components of the oil. Further, the tests indicate, that the oil is well-suited for the incorporation into many taste-sensitive foods that are normally being kept refrigerated.

20 Use of refined oil

The invention includes refined marine mammal oil or fish oil obtained according to the procedure outlined in the application. The oil is useful in the pharmaceutical, health food, supplement and food industries. The invention includes the use of an oil of the invention for the preparation of a medicament for the treatment 25 of a disease in a mammal. The invention also includes an oil of the invention for use as an active pharmaceutical substance.

The oil may be further processed after refining. For example, concentrate of omega-3 fatty acids could be prepared by known techniques to concentrate the omega-3 fatty acid content up to about 80% or 90%. One or more omega-3 fatty acids may also be separated from the oil. The separated fatty acids may then be used 30 as nutritional supplements, neutraceuticals or pharmaceutical compositions in a similar manner as the whole refined oil.

Pharmaceutical, nutritional supplement uses**(i) Formulation**

The refined oil may be administered to a mammal without formulation.

5 Pharmaceutical compositions using the oil could include the oil and an acceptable vehicle or excipient (Remington's Pharmaceutical Sciences 18th ed, (1990, Mack Publishing Company) and subsequent editions). Vehicles include saline and D5W (5% dextrose and water). Excipients include additives such as an antioxidant (such as a mixed tocopherol, which includes alpha-, beta-, delta- and gamma-tocopherol),
10 buffer, solubilizer, suspending agent, emulsifying agent, viscosity controlling agent, flavor, lactose filler, antioxidant, preservative or dye. The oil may be formulated in solid or semisolid form, for example pills, tablets, creams, ointments, powders, emulsions, gelatin capsules, capsules or gels. Capsules are the preferred dosage form. The capsules may include gelatin, glycerin, purified water and/or mixed tocopherol.
15 Routes of administration include oral, topical, or transdermal administration optionally in combination with one or more bioactive compound(s). Preferred bioactive molecules are at least one of coenzyme Q10 and an antioxidant (e.g. mixed tocopherol). These formulations may also be used as a nutritional supplement or neutraceutical. The methods for the preparation of pharmaceutically acceptable
20 compositions which can be administered to patients are known in the art.

The pharmaceutical compositions can be administered to humans or animals. Dosages to be administered depend on individual patient condition, indication of the drug, physical and chemical stability of the composition, toxicity, the desired effect and on the chosen route of administration (Robert Rakel, ed., Conn's Current Therapy 25 (1995, W.B. Saunders Company, USA)). The pharmaceutical compositions are used as described in the following section.

The refined oil is useful to prevent, provide therapy for, or treat diseases, disorders, conditions and abnormal physical states where other omega-3 fatty acids and oils have proven useful. The oil is also a useful nutritional supplement for
30 healthy individuals.

Some conditions typical of a deficiency in essential fatty acids are fatigue, depression, dry skin and hair, dry mucous membranes, cracked nails, indigestion,

constipation and lack of endurance. The oil of the invention is useful to treat these conditions, whether or not they are caused by fatty acid deficiency.

Long term essential fatty acid deficiency is associated with a higher risk of chronic degenerative diseases. At least 60 medical conditions are linked to this

5 deficiency or alternatively have been identified as benefiting from Omega-3 supplementation (Murray ND). Therapy, treatment or nutritional supplementation by administration of the oil (or omega-3 fatty acids separated from the oil) may be used to prevent or treat each of the diseases, disorders, conditions or abnormal physical states described in this application. The appropriate approach will be apparent-based
10 on the description in this application and the skill in the art. The diseases, disorders, conditions or abnormal physical states include hyperaggregation, cardiovascular disease and disorders (including hypercholesterolemia, atherosclerosis (Kanayasu-Toyoda T et al.; Dyerberg J) high triglyceride levels, impaired ability to circulate blood to the extremities with the consequent atrophy of nerve cells-a particular
15 problem for diabetics, and high blood pressure), atopic dermatitis, multiple sclerosis and premenstrual syndrome, acne, allergic and inflammatory conditions (including psoriasis and eczema (such as atopic dermatitis (endogenous eczema), seborrheic dermatitis and photo-dermatitis)), asthma (including difficulty breathing/shortness of breath, wheezing, coughing, production of bronchial mucus), autoimmune diseases
20 (including multiple sclerosis (e.g. prevented in part by oil promotion of normal myelin formation)), lupus and some cancers), Alzheimer's disease, arthritis (particularly rheumatoid arthritis and osteo-arthritis), atherosclerosis, breast cysts, cancer (including breast cancer), cystic fibrosis, diabetes, hypertension, hyperactivity, intestinal disorders, kidney dysfunction, leukemia, myopathy, obesity, homocystinuria
25 and vascular disease. There is empirical evidence from health practitioners that seal oil has achieved remarkable results in a relatively short time frame among diabetics, persons with inadequate endocrine functions or enzyme functions, arthritic, psoriasisitic and hypertensive patients. Administration of omega-3 fatty acids can change the chemical composition of organs (Murphy MG et al).

30

(ii) Diabetes

Diabetes is a disease which strongly benefits from administration of the oil of the invention. It is among the fastest growing medical conditions worldwide. Among the best known benefits of omega-3 seal oil is its ability to help restore blood

circulation to the extremities (poor circulation can be a chronic problem among diabetics). Without proper circulation, nerve cells can atrophy and in the most severe cases result in blindness and the amputation of limbs. Omega-3 seal oil, preferably in conjunction with other dietary measures and exercise can help prevent or delay the 5 onset of the disease.

(iii) Children

Omega-3 deficiency, particularly DPA & DHA deficiency can also contribute to problems in fetal development, vision (e.g. visual acuity), coronary heart disease and mental development in infants and children (Crawford MA et al.). Omega-3 fatty 10 acids are critical to support proper child development and growth (for example, DHA is rapidly incorporated into the lipids of the brain and retina during the last trimester of pregnancy and the first year after birth.). They also protect against diseases such as those described above, and in particular hypertension, inflammation, allergies (Yu G, Bjorksten B; Yu G, Bjorksten B) autoimmune diseases, weakened immune system, 15 liver degeneration, kidney degeneration, growth retardation, learning disorders, hypertension, eczema (Businco L et al.) and cardiovascular disease. Recent research has identified docosapentaenoic acid (DPA), for which EPA is a precursor, as among the most important of the EFAs in maintaining the required supple and pliable characteristics of interior vascular walls.

20 Infants, particularly premature infants, low birth weight infants, or infants for whom human breast milk is not available, benefit from infant formulas that include the oil of the invention. Malnourished children also benefit (Leichsenring M et al.). The formulas preferably use the oils to produce a milk with fatty acid composition similar to breast milk (preferably with additional omega-3 fatty acids; Henderson RA 25 et al.). The formulas may be made rich in omega-3 fatty acids DHA, for example, to develop the nervous system and visual acuity.

Food uses

The refined oil (or omega-3 fatty acids separated from the oil) is useful as a 30 food additive, in order to fortify the nutritional content of food. Preferred foods include those with a short shelf life, such as a milk product or a grain product. Suitable milk products include skim milk, whole milk, 1% milk, 2% milk, sour cream, coffee cream, whipping cream, powdered milk, yogurt and ice cream. Milk prepared with the refined oil does not have a fishy taste and the oil does not add any odour.

Preferred grain products include bread and flour. Bread prepared with the refined oil of the invention does not have a fishy taste and the oil does not add any odour. Foods with a longer shelf life such as salad dressing can also be fortified by the oil. Fruit and vegetable juices, such as orange juice, may also be fortified with the oil.

5 The refined oil is also suitable for addition to an animal, bird or fish feed. The invention includes a food product, comprising the flesh or egg of an animal, bird or fish where the animal is raised by feeding the animal the refined oil.

The oil may be microencapsulated according to known techniques for use in foods, pharmaceutical compositions or personal care products.

10 **Formulation of a personal-care product with oil**

Compositions for hair or other personal care may be prepared by adding oil in hair rinses, aerosol sprays, mists, gels, mousses, shampoos, conditioners, lotions, films, emulsions or colouring products.

The composition may be used in topical creams, such as moisturizers, makeup.
15 Makeup products such as foundation, lipstick, eyeshadow, blush, moisturizing creams and lotions may also contain the oil of the invention. These are formulated according to known methods for makeup products such as those for preparation of an anhydrous or aqueous solid or paste, emulsion, suspension or dispersion.

20 The present invention has been described in detail and with particular reference to the preferred embodiments; however, it will be understood by one having ordinary skill in the art that changes can be made without departing from the spirit and scope thereof.

25 All publications, patents and patent applications, including Canadian application no. 2,260,397, are incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.

References

1. Benistant C, Achard F, Ben Slama S, Lagarde M, Docosapentaenoic acid (22:5,n-3): metabolism and effect on prostacyclin production in endothelial cells. *Prostaglandins Leukot Essent Fatty Acids* 1996 Oct;55(4):287-92.
- 5 2. Shukla VKS and Perkins EG, The presence of oxidative polymeric materials in encapsulated fish oils. *Lipids* 26, 23-26, 1991.
3. Fritshe KL and Johnston PV, Rapid autoxidation of fish oil in diets without added antioxidants. *J. Nutr* 118, 425-426, 1988.
- 10 4. Harats D, et al., Fish oil ingestion in smokers and nonsmokers enhances peroxidation of plasma lipoproteins. *Atherosclerosis* 90, 127-139, 1991.
5. Kromann N and Green A., Epidemiological studies in the Upernivik district, Greenland. *Acta Med Scand* 208, 401-406, 1980.
6. Kromhout D, Bosscherier EB, and Delzenne-Coulander C, Inverse relation 15 between fish oil consumption and 20 year mortality from coronary heart disease. *N. Engl J Med* 312, 1205-1209, 1985.
7. Seidelin KN, Myrup B, and Fischer-Hansen B, N-3 fatty acids in adipose tissue and coronary artery disease are inversely correlated. *Am J Clin Nutr* 55, 1117-1119, 1992.
- 20 8. Ornish E, et al., Can lifestyle changes reverse coronary heart disease. *Lancet* 336, 129-133, 1990.
9. Belch JF, et al., Effects of altering dietary essential fatty acids on requirements for non-steroidal anti-inflammatory drugs in patients with rheumatoid arthritis: A double blind placebo controlled study. *Annals Rheum Dis* 47, 96-104, 1988.
- 25 10. Murray ND, "The Encyclopedia of Nutritional Supplements"
11. Kanayasu-Toyoda T et al., "Docosapentaenoic acid (22:5, n-3), an elongation metabolite of eicosapentaenoic acid (20:5, n-3), is a potent stimulator of endothelial cell migration on pretreatment in vitro.", *Prostaglandins Leukot Essent Fatty Acids* 1996 May; 54(5):319-25 Med Res 1989 Apr;48(2):47-54.
- 30 12. Dyerberg J, "Coronary heart disease in Greenland Inuit: a paradox. Implications for western diet patterns."
13. Murphy MG et al., "Diets enriched in menhaden fish oil, seal oil, or shark liver oil have distinct effects on the lipid and fatty-acid composition of guinea pig heart.". *Mol Cell Biochem* 1997 Dec;177(1-2):257-69.

14. Crawford MA et al., "Essential fatty acids and fetal brain growth.", *Lancet* 1976 Feb 28;1(7957):452-3.
15. Yu G et al., "Polyunsaturated fatty acids in school children in relation to allergy and serum IgE levels.", *Pediatr Allergy Immunol* 1998 Aug;9(3):133-8.
16. Yu G et al., "Serum levels of phospholipid fatty acids in mothers and their babies in relation to allergic disease.", *Eur J Pediatr* 1998 Apr;157(4):298-303.
17. Businco L et al., "Breast milk from mothers of children with newly developed atopic eczema has low levels of long chain polyunsaturated fatty acids.", *J Allergy Clin Immunol* 1993 Jun;91(6):1134-9.
18. Leichsenring M et al., "Polyunsaturated fatty acids in erythrocyte and plasma lipids of children with severe protein-energy malnutrition.", *Acta Paediatr* 1995 May;84(5):516-20.
- 15 19. Henderson RA et al., "Effect of fish oil on the fatty acid composition of human milk and maternal and infant erythrocytes.", *Lipids* 1992 Nov;27(11):863-9.

THE ASPECTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY
OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

1. A process of refining marine oil including:
 - contacting the oil with an effective amount of a silica under a vacuum ;
- 5 • contacting the oil with an effective amount of a bleaching clay;
- separating the silica from the oil;
- separating the clay from the oil.
2. The process of claim 1
 wherein the process is performed without the use of an exogenously added alkali or
10 acid.
3. The process of claim 1, consisting of:
 - contacting the oil with an effective amount of a silica under a vacuum;
 - contacting the oil with an effective amount of a bleaching clay;
 - separating the silica from the oil;
 - 15 • separating the clay from the oil.
4. The process of any of claims 1 to 3, wherein the oil is contacted with the silica
 before the oil is contacted with the bleaching clay.
5. The process of any of claims 1 to 4, wherein the bleaching clay is under a vacuum.
6. The process of any of claims 1 to 5, wherein the silica includes a silica gel.
- 20 7. The process of any of claims 1 to 6, wherein the oil is obtained from the fatty
 tissue of the marine mammal.
8. The process of claim 7, wherein the marine mammal is a seal.
9. The process of claim 8, wherein the seal is selected from the group consisting of
 harp seal, harbour seal, ringed seal, hooded seal and grey seal.
- 25 10. The process of any of claims 1 to 6, wherein the oil is obtained from the fatty
 tissue of a fish.

11. The process of claim 10, wherein the fish is selected from the group consisting of salmon and mackerel.
12. The process of any of claims 1 to 11, wherein the silica and clay are separated from the oil by filtration and/or centrifugation.
- 5 13. The process of any of claims 6 to 12 wherein the effective amount of silica gel is from about 0.01% to 3% by weight of oil.
14. The process of any of claims 6 to 13 wherein the silica gel is TriSyl S 627 or a Sorbsil silica.
15. The process of any of claims 1 to 14, wherein the oil is contacted with the silica
- 10 for about 1 to 60 minutes.
16. The process of any of claims 1 to 15, wherein the effective amount of bleaching clay is from about 0.1% to 3% by weight of oil.
17. The process of any of claims 1 to 16, wherein the clay comprises Tonsil Supreme 120 FF, a Filtrol clay or a Pur-Flo clay.
- 15 18. The process of any of claims 1 to 17, wherein the oil is heated to about 75°C to 110°C after the oil contacts the bleaching clay.
19. The process of any of claims 1 to 18, wherein the oil contacts the bleaching clay for about 5 to 30 minutes.
20. The process of any of claims 1 to 19, including deodorizing the oil.
21. The process of claim 20, wherein deodorization is carried out in the temperature range of about 150°C to 245°C.
22. The process of claim 20 or claim 21, wherein deodorization is carried out at a pressure of about 0.1 mm Hg to 7 mm Hg.
23. The process of claim 22, wherein the oil is exposed to the temperature and
- 25 pressure for from about 0.5 minutes to 10 minutes.
24. The process of any of claims 1 to 23, wherein oil shrinkage is less than about 1.5% + 1.5 x FFA% in the oil by weight of crude oil.

25. The process of any of claims 1 to 24, wherein the refined oil is essentially free of proteinaceous material, phosphatidic material and mucilagenous material, trace metals and very low in colour.
26. The process of any of claims 1 to 25, wherein the refined oil includes a free fatty acid content below 0.25% if the oil is deodorized and a free fatty acid content below 2% if the oil is not deodorized, a peroxide value less than about 1.5 me/kg, an anisidine value below 5 and iron below 0.1 mg/kg and a bland flavor.
5
27. The process of any of claims 1 to 26, wherein the refined oil includes copper below about 0.05 mg/kg, phosphorous below about 0.2 mg/kg and is essentially free of pesticides.
10
28. The process of any of claims 1 to 27, wherein the omega-3 fatty acid concentration is substantially unchanged from the crude oil.
29. The process of claim 28, wherein the omega-3 fatty acid concentration is changed by less than 1% absolute from the crude oil.
- 15 30. The process of any of claims 1 to 29, wherein the oil has a flavor stability measured by organoleptic testing in which no strong flavor development occurs for at least about 2 months when the oil is stored at ambient temperatures and substantially protected from harmful light radiation and air.
31. A refined marine mammal oil or seal oil prepared by the process of any of claims
20 1 to 30.
32. A refined marine mammal oil or fish oil obtained according to a process described in the application.
33. A refined oil including a free fatty acid content below about 0.25% after deodorization and a free fatty acid content below 2% if the oil is not deodorized.
- 25 34. A refined oil including a peroxide value less than about 1.6 me/kg.
35. A refined oil including an anisidine value below about 5.
36. The refined oil of any of claims 31 to 35, wherein the refined oil is a seal oil and includes a free fatty acid content below 0.25% after deodorization and a free fatty acid content below 2% if the oil is not deodorized, a peroxide value less than

about 1.5 me/kg, an anisidine value below 5, iron concentration below 0.1 mg/kg and a bland flavor.

37. The oil of any of claims 31 to 36, wherein the refined oil includes copper below about 0.05 mg/kg, phosphorous below about 0.2 mg/kg, and pesticides essentially undetectable by chromatography.

5 38. The refined oil of any of claims 31 to 37, wherein the omega-3 fatty acid concentration is substantially unchanged from the crude oil.

39. The refined oil of any of claims 31 to 38, wherein the oil has a flavor stability measured by organoleptic testing in which no strong flavor development occurs 10 for at least about 2 months when the oil is stored at ambient temperatures and protected from harmful light radiation and air.

40. The refined oil of any of claims 31 to 39, wherein the oil includes marine mammal oil.

41. The refined oil of claim 40, wherein the marine mammal oil includes seal oil.

15 42. The refined oil of claim 41, wherein the seal oil is selected from the group consisting of harp seal, harbour seal, hooded seal, grey seal and ringed seal.

43. The refined oil of any of claims 31 to 39, wherein the oil includes fish oil.

44. The refined oil of claim 43, wherein the fish oil is selected from the group consisting of salmon and mackerel.

20 45. An omega-3 fatty acid concentrate, comprising omega-3 fatty acids of the refined oil of any of claims 31 to 44, concentrated by up to about 80% or 90%.

46. A process for preparing an omega-3 fatty acid concentrate, comprising concentrating the omega-3 fatty acids of the refined oil of any of claims 31 to 44 by up to about 80% or 90%.

25 47. Omega-3 fatty acids isolated from the oil of any of claims 31 to 45.

48. A pharmaceutical composition including the refined oil of any of claims 31 to 45 or the omega-3 fatty acids of claim 47, and a carrier.

49. The pharmaceutical composition of claim 48, and carriers and/or diluents for adapting it for oral, nasal, pulmonary, rectal, ocular, transdermal or parenteral

administration optionally in combination with one or more bioactive compound(s).

50. The pharmaceutical composition of claim 49, wherein the bioactive molecule is selected from the group consisting of at least one of coenzyme Q10 and an antioxidant.
- 5 51. A nutritional supplement including the oil of any of claims 31 to 45 or the omega-3 fatty acids of claim 47.
52. A nutritional supplement including the oil of any of claims 31 to 45 or the omega-3 fatty acids of claim 47 and coenzyme Q10 or an antioxidant.
- 10 53. A capsule including the oil of any of claims 31 to 45 or the omega-3 fatty acids of claim 47.
54. The capsule of claim 53, wherein the capsule comprises a gelatin capsule.
55. A food product including the oil of any of claims 31 to 45 or the omega-3 fatty acids of claim 47.
- 15 56. The food product of claim 55, wherein the food product is selected from the group consisting of a milk product, a salad dressing and a grain product.
57. The food product of claim 56, wherein the milk product is selected from the group consisting of skim milk, whole milk, 1% milk, 2% milk, sour cream, coffee cream, whipping cream, powdered milk, yogurt and ice cream.
- 20 58. The food product of claim 56, wherein the grain product is selected from the group consisting of bread and baked food.
59. An animal, bird or fish feed comprising the oil of any of claims 31 to 45 or the omega-3 fatty acids of claim 45.
60. A food product, comprising the flesh or egg of an animal, bird or fish wherein the animal is raised by feeding the animal the oil of any of claims 31 to 45, the omega-3 fatty acids of claim 47 or the feed of claim 59.
- 25 61. A method of medical treatment, therapy or prophylaxis of a disease, condition, disorder or abnormal physical state comprising administering an effective amount of the oil, pharmaceutical composition, nutritional supplement, capsule or food product of any of claims 31 to 45, 47 to 58 or 60 to a mammal.
- 30

62. The method of claim 61, wherein the disease, disorder or abnormal physical state includes one or more characteristics selected from the group consisting of inadequate dietary omega-3 fatty acids, an imbalance of essential fatty acids, a deficiency of one or more essential fatty acids including EPA, DHA, DPA, 18:3
5 omega-3 fatty acid and 18:4 omega-3 fatty acid.

63. The method of claim 62, wherein the disease is selected from the group consisting of heart disease, diabetes, hypertriglyceridemia, hypertension, arthritis, psoriasis, stroke, inflammation, immune system disorders and nervous system disorders.

64. A method of medical treatment or prophylaxis of risk factors for a cardiovascular
10 disease, disorder or abnormal physical state, comprising administering an effective amount of the oil, pharmaceutical composition, nutritional supplement, capsule or food product of any of claims 31 to 45, 47 to 58 or 60 to a mammal.

65. A method for promoting normal brain, immune system and heart development in a patient which comprises administering to a mammal an effective amount of the
15 oil, pharmaceutical composition, nutritional supplement, capsule or food product of any of claims 31 to 45, 47 to 58 or 60 to a mammal.

66. A method of prophylaxis of a disease, disorder or abnormal physical state in a fetus, infant or child comprising administering an effective amount of the oil, pharmaceutical composition, nutritional supplement, capsule or food product of
20 any of claims 31 to 45, 47 to 58 or 60 to a mammalian mother.

67. The method of any of claims 61 to 66, wherein the administered oil includes omega-3 fatty acids selected from the group consisting of EPA, DHA, DPA, 18:3 omega-3 long chain fatty acids and 18:4 omega-3 long chain fatty acids.

68. The method of any of claims 61 to 66, wherein the amount of oil administered is
25 adequate to provide about 1.8 to 2.5 g or more of omega-3 essential fatty acids per day.

69. The method of any of claims 61 to 66, wherein the amount of harp seal oil contains omega-3 essential fatty acids in the range of about 20% to 24% by weight and wherein the amount of oil administered is up to about 10g/day.

30 70. The method of any of claims 61 to 66, wherein the amount of harp seal oil contains omega-3 essential fatty acids in the range of about 20% to 24% by weight

and wherein the amount of oil administered is less than or greater than about 10g/day.

71. A refined seal oil having about the properties of the seal oil in Table 1, Table 2, Table 3 and/or the seal oil of the invention in Table 4.

5 72. The process of any of claims 1 to 30, wherein the oil comprises crude oil or foundation oil.

73. The use of the oil of any of claims 31 to 45 or the omega-3 fatty acids of claim 47 for the preparation of a medicament for the treatment of a disease in a mammal.

74. An oil of any of claims 31 to 45 or the omega-3 fatty acids of claim 47 for use as
10 an active pharmaceutical substance.

